

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K</b>		<b>A2</b>	(11) International Publication Number: <b>WO 96/01614</b>
			(43) International Publication Date: 25 January 1996 (25.01.96)
(21) International Application Number: <b>PCT/US95/08620</b>			NY 11765 (US). VILLEPONTEAU, Bryant [US/US]; 1371 Greenbrier Road, San Carlos, CA 94070 (US).
(22) International Filing Date: 7 July 1995 (07.07.95)			(74) Agents: GRANAHAH, Patricia et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).
(30) Priority Data:			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
08/272,102 7 July 1994 (07.07.94) US			
08/330,123 27 October 1994 (27.10.94) US			
08/387,524 13 February 1995 (13.02.95) US			
08/485,778 7 June 1995 (07.06.95) US			
(71) Applicants (for all designated States except US): COLD SPRING HARBOR LABORATORY [US/US]; P.O. Box 100, Cold Spring Harbor, NY 11724 (US). GERON CORPORATION [US/US]; 200 Constitution Drive, Menlo Park, CA 94025 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): ANDREWS, William, H. [US/US]; 6102 Park Avenue, Richmond, CA 94805 (US). AVILLON, Ariel, Athena [US/US]; 14 Nordham Road, Shoreham, NY 11786 (US). FENG, Junli [CN/US]; 1371 Greenbrier Road, San Carlos, CA 94070 (US). FUNK, Walter [CA/US]; 4858 Mendota Street, Union City, CA 94587 (US). GREIDER, Carol [US/US]; 87 Bay Drive East, Huntington, NY 11743 (US). MARHUENDA, Maria, Antonia, Blasco [ES/US]; 297 Mill Hill Road, Mill Neck,			<b>Published</b> Without international search report and to be republished upon receipt of that report.
(54) Title: RNA COMPONENT OF TELOMERASE			
(57) Abstract			
Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.			

Best Available Copy

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## RNA Component of Telomerase

### Background of the Invention

The DNA at the ends or telomeres of the chromosomes of eukaryotes usually consists of tandemly repeated simple sequences. Telomerase is a ribonucleoprotein enzyme that synthesizes one strand of the telomeric DNA using as a template a sequence contained within the RNA component of the enzyme. See Blackburn, E.H. (1992) *Annu. Rev. Biochem.* 61:113-129, incorporated herein by reference.

10 The RNA component of a mammalian telomerase has not been reported in the scientific literature to date, although, human and mouse telomerases are known to synthesize telomeric repeat units with the sequence 5'-TTAGGG-3'. See Morin, G.B (1989) *Cell* 59:521-529; Morin, G.B. (1991) *Nature* 353:454-456; Prowse, et al. (1993) *PNAS* 90:1493-1497, incorporated herein by reference. This knowledge has not been sufficient to enable the isolation and identification of the remainder of the nucleotide sequence of the RNA component of either of these

20 telomerases. The RNA component of the telomerase enzymes of *Saccharomyces cerevisiae*, certain species of *Tetrahymena*, as well as that of other ciliates, such as *Oxytricha*, *Euplotes* and *Glaucoma*, has been sequenced and reported in the scientific literature. See Singer, M.S. and D. E. Gottschling (1994) *Science* 266:404-409; Lingner et al. (1994) *Genes & Development* 8:1984-1988; Greider, C.W. and E.H. Blackburn (1989) *Nature* 337:331-337; Romero, D.P. and E.H. Blackburn (1991) *Cell* 67:343-353; Shippen-Lentz, D. and E.H. Blackburn (1990) *Science* 247:546-552. The

30 teachings of each of these references are incorporated herein by reference. The telomerase enzymes of these

-2-

ciliates synthesize telomeric repeat units distinct from that in mammals.

There is a great need for more information about mammalian telomerase. Despite the seemingly simple nature of the repeat units of telomeric DNA, scientists have long known that telomeres have an important biological role in maintaining chromosome structure and function. More recently, scientists have speculated that loss of telomeric DNA may act as a trigger of cellular senescence and aging and that regulation of telomerase may have important biological implications. See Greider, C.W. (1994) *Curr. Opin. Genetics Devel.* 4:203-211; Harley, C.B. (1991) *Mutation Res.* 256:271-282; Harley, C.B. et al. (1990) *Nature* 345:458-460, incorporated herein by reference.

Methods for detecting telomerase activity, as well as for identifying compounds that regulate or affect telomerase activity, together with methods for therapy and diagnosis of cellular senescence and immortalization by controlling telomere length and telomerase activity, have also been described. See PCT patent publication No. 93/23572, published November 25, 1993, incorporated herein by reference.

Significant improvements to and new opportunities for telomerase-mediated therapies and telomerase assays and screening methods could be realized if nucleic acids comprising the RNA component and/or encoding the protein components of telomerase were available in pure or isolated form and the nucleotide sequences of such nucleic acids were known.

### 30 Summary of the Invention

In a first aspect, the present invention provides the RNA component of, as well as the gene for the RNA component of, human telomerase in substantially pure form, as well as nucleic acids comprising all or at least a portion of the

-3-

nucleotide sequence of the RNA component of human telomerase (hTR). The present invention also provides the RNA component of, and the gene for the RNA component of, mouse telomerase in substantially pure form, as well as

5 nucleic acids comprising all or at least a portion of the nucleotide sequence of the RNA component of mouse telomerase (mTR). The present invention further provides RNA component nucleic acids and genes encoding such RNA component nucleic acids or portions thereof, from other

10 species, including the RNA component of rat (rTR), Chinese hamster (cTR) and bovine telomerase (bTR). The RNA components include, but are not limited to, the RNA components of mammals, such as primates. Other nucleic acids of the invention include nucleic acids with sequences

15 complementary to the RNA component; nucleic acids with conserved nucleotide residues of RNA components; nucleic acids with sequences related to, but distinct from, nucleotide sequences of the RNA components and which interact with the RNA component or the gene for the RNA

20 component of the protein components of human telomerase in a useful way; and nucleic acids that do not share significant sequence homology or complementarity to the RNA component or the gene for the RNA component but act on the RNA component in a desired and useful way. As described

25 more fully below, the nucleic acids of the invention include both DNA and RNA molecules and modified analogues of either and serve a variety of purposes.

Thus, one type of nucleic acid of the invention is an antisense oligonucleotide that can be used *in vivo* or *in*

30 *vitro* to inhibit the activity of a mammalian telomerase, such as human telomerase. Such oligonucleotides can block telomerase activity in a number of ways, including by preventing transcription of the telomerase gene (for instance, by triple helix formation) or by binding to the

35 RNA component of telomerase in a manner that prevents a

-4-

functional ribonucleoprotein telomerase from assembling or prevents the RNA component, once assembled into the telomerase enzyme complex, from serving as a template for telomeric DNA synthesis. Typically, and depending on mode  
5 of action, these oligonucleotides of the invention comprise a specific sequence of from about 10 to about 25 to 200 or more nucleotides that is either identical or complementary to a specific sequence of nucleotides in the RNA component of telomerase or the gene for the RNA component of  
10 telomerase.

Another type of nucleic acid of the invention is a ribozyme able to cleave specifically the RNA component of a mammalian telomerase, rendering the enzyme inactive. Yet another type of nucleic acid of the invention is a probe or  
15 primer that binds specifically to the RNA component of a mammalian telomerase and so can be used, e.g., to detect the presence of telomerase in a sample. Finally, nucleic acids of the invention include recombinant expression plasmids for producing the nucleic acids of the invention.  
20 One type of such a plasmid is a plasmid used for human gene therapy or for use in mouse, rat, Chinese hamster and bovine or other mammalian experimental models. Plasmids of the invention for human gene therapy or mammalian models come in a variety of types, including not only those that  
25 encode antisense oligonucleotides or ribozymes, but also those that drive expression of the RNA components of mammalian telomerase or a deleted or otherwise altered (mutated) version of the RNA component of human, mouse, rat, Chinese hamster or bovine (or other species with RNA  
30 component sequences homologous to these RNA components and/or which encode a functional RNA component when combined with the appropriate telomerase protein component) telomerase or the gene for the same.

In a second aspect, the invention provides methods for  
35 treating a condition associated with the telomerase

-5-

activity within a cell or group of cells by contacting the cell(s) with a therapeutically effective amount of an agent that alters telomerase activity in that cell. Such agents include the telomerase RNA component-encoding nucleic acids, triple helix-forming oligonucleotides, antisense oligonucleotides, ribozymes, and plasmids for human gene therapy or mammalian models described above. In a related aspect, the invention provides pharmaceutical compositions comprising these therapeutic agents together with a pharmaceutically acceptable carrier or salt.

In a third aspect, the invention provides diagnostic methods for determining the level, amount, or presence of the RNA component of human telomerase, mouse telomerase, telomerase, or telomerase activity in a cell, cell population, or tissue sample, or an extract of any of the foregoing. In a related aspect, the present invention provides reagents for such methods (including the primers and probes noted above), optionally packaged into kit form together with instructions for using the kit to practice the diagnostic method.

In a fourth aspect, the present invention provides recombinant telomerase preparations and methods for producing such preparations. Thus, the present invention provides a recombinant human, mouse, rat, Chinese hamster, bovine or other mammalian telomerase that comprises the protein components of these telomerases as well as the protein components of telomerase from another mammalian species with an RNA component substantially homologous to the RNA component of human, mouse, rat, Chinese hamster, bovine or other telomerase in association with a recombinant RNA component of the inventions. Such recombinant RNA component molecules of the invention include those that differ from naturally-occurring RNA component molecules by one or more base substitutions, deletions, or insertions, as well as RNA component

-6-

molecules identical to a naturally-occurring RNA component molecule that are produced in recombinant host cells. The method for producing such recombinant telomerase molecules comprises transforming a eukaryotic host cell that

5 expresses the protein components of telomerase with a recombinant expression vector that encodes an RNA component molecule of the invention, and culturing said host cells transformed with said vector under conditions such that the protein components and RNA component are expressed and

10 assemble to form an active telomerase molecule capable of adding sequences (not necessarily the same sequence added by native telomerase) to telomeres of chromosomal DNA.

In a fifth aspect, the invention provides methods for purifying the protein components of human telomerase as

15 well as the protein components of telomerase from another mammalian species with an RNA component substantially homologous to the RNA component of human telomerase. The present invention also provides methods for isolating and identifying nucleic acids encoding such protein components.

20 In related aspects, the present invention provides purified human, mouse, rat, Chinese hamster, or bovine telomerase and purified telomerase of other mammalian species with an RNA component substantially homologous to the coding regions of the RNA components of human, mouse, rat, Chinese

25 hamster, bovine or other mammalian telomerase, as well as purified nucleic acids that encode one or more components of such telomerase preparations. The present invention also provides pharmaceutical compositions comprising as an active ingredient the protein components of telomerase or a

30 nucleic acid that encodes or interacts with a nucleic acid that encodes a protein component of telomerase.

In a sixth aspect, the invention provides a mammalian model system through which telomere regulation can be studied *in vivo*. A mouse, rat or hamster model,

35 particularly a knockout mouse, offers an excellent system



-7-

in which the role of telomerase in aging and immortalization can be directly tested. Altered telomerase and compounds that affect the telomerase activity can be used to determine the effects of telomerase on both cell  
5 viability and organismal development.

Other features and advantages of the invention will be apparent from the following description of the drawings, preferred embodiments of the invention, the examples, and the claims.

#### 10 Brief Description of the Figures

Figures 1A-1B are the DNA sequence (SEQ ID NO:1) encoding the human telomerase RNA component.

Figure 2 is the RNA sequence (SEQ ID NO:2) of the human telomerase RNA component.

15 Figure 3 is the DNA sequence (SEQ ID NO:3) encoding the mouse telomerase RNA component.

Figure 4 is the RNA sequence (SEQ ID NO:4) of the mouse telomerase RNA component.

Figure 5 is a comparison of the mouse and human  
20 ribonucleotide sequences that comprise the RNA component of telomerase. The coding region for each begins at the +1 position indicated.

Figure 6 is a diagram of a targeting construct for knocking out the mouse telomerase RNA component.

25 Figure 7A-7B is a comparison of the DNA sequences encoding human, mouse, rat (SEQ ID NO:5), Chinese hamster (SEQ ID NO:43) and bovine (SEQ ID NO:44) telomerase RNA components.

Figure 8A-8E shows the putative secondary structure  
30 folding of human, mouse, rat, Chinese hamster and bovine telomerase RNA components.

#### Detailed Description of the Invention

The present invention provides methods, reagents, and

-8-

pharmaceutical compositions relating to the ribonucleoprotein mammalian telomerases. The invention in part arises out of the cloning and isolation of the RNA components of mammalian telomerases, particularly human, mouse, rat, Chinese hamster and bovine telomerases and the genes for those RNA components. The nucleotide sequences of the RNA components of both human and mouse telomerase are shown in Figures 2 and 4, respectively. The sequences of the rat, Chinese hamster and bovine telomerase RNA components are shown in Figure 7A-7B. For convenience, the sequences are shown using the standard abbreviations for nucleotides (A is adenine, G is guanine, C is cytidine, T is thymine, and U is uridine). The DNA sequences for the human and mouse telomerase RNA genes are shown in Figures 1A-1B and 3, respectively.

The sequences in Figures 2, 4, and 7 are shown in the 5'-3' direction and are numbered for reference. The template sequence of the human RNA component (Figure 2) is believed to be located within the region defined by nucleotides 50-60 (5'-CUAACCCUAAC-3'), which is complementary to a telomeric sequence composed of about one-and-two-thirds telomeric repeat units.

These sequences were derived from cDNA clones and from the genomic clone of the RNA components. When the RNA component is first transcribed from the corresponding human or mouse gene, at least some of the RNA transcripts produced are much longer than the ~560 and ~535 nucleotide sequences shown and in fact may comprise more than 1000 nucleotides. However, fully functional telomerase molecules can be assembled from transcripts consisting of the ~560 and ~535 nucleotide sequences shown in the figures.

The 3'-end of the RNA component in native human telomerase is believed to lie within the region defined by nucleotides 514-559 in the human sequence above; one

analysis suggests that the 3'-end may be the U residue at nucleotide 538. Recombinant RNA component molecules comprising less than nucleotides 1-559 of the human sequence shown above can also be used to prepare active  
5 telomerase.

#### The RNA Component of Human Telomerase

The cloning of the RNA component of human telomerase required a novel method involving negative selection and cycles of positive selection, described below. Initially,  
10 however, an attempt was made to clone the RNA component using reverse transcription and a method for cloning the ends of cDNA called "5'-RACE PCR amplification". The reverse transcription reaction was initiated with a primer identical to the repeat unit in the single-strand portion  
15 of human telomeric DNA and thus complementary to a sequence believed to be present in the RNA component of human telomerase. The primer also comprised, at its 5'-end, a sequence corresponding to a restriction enzyme recognition site. However, when the cDNA produced by the reverse  
20 transcription reaction and PCR amplification was examined by gel electrophoresis and nucleotide sequence analysis of the bands of nucleic acid present in the gel, only ribosomal RNA sequences were detected. Similar problems were encountered when variations of this 5'-RACE approach  
25 were attempted using nested primers.

The successful cloning effort began with the preparation of cDNA from purified preparations of human telomerase, as well as from cell lines that have human telomerase activity and from cell lines that do not have  
30 detectable human telomerase activity. The method used to prepare the cDNA is described in detail in Example 1, below. Two negative selection steps and successive cycles of positive selection were used in conjunction with the cDNA preparations from the two human cell lines to lower

-10-

the concentration of unwanted sequences and to raise the concentration of the desired RNA component sequences.

The negative selection steps involved the preparation of biotinylated PCR product from cDNA prepared from a human  
5 cell line that does not have detectable telomerase activity. The biotinylated PCR product was denatured and then rehybridized in a solution comprising a much lower concentration of non-biotinylated PCR product (100 biotinylated product:1 non-biotinylated product) from cDNA  
10 prepared from a human cell line that does have telomerase activity. Given the possibility that the telomerase negative cell line might contain some low amount of the RNA component, the hybridization step was conducted to discriminate or select against only RNA expressed  
15 abundantly in both cell lines. After hybridization to a C<sub>0</sub>t selected to allow hybridization of the most abundantly expressed RNA, the unwanted material was removed by binding to streptavidinylated magnetic particles; the supernatant remaining after particle collection contained the desired  
20 cDNA for the RNA component of human telomerase. The process for PCR amplification of cDNA is described in Example 2, below.

This material was further enriched for the desired cDNA by successive cycles of positive selection. In the  
25 positive selection step, a biotinylated probe complementary to the predicted template sequence in the RNA component of human telomerase was hybridized to PCR product from an enriched (by negative selection) sample of the PCR-amplified cDNA from a human cell line that has telomerase  
30 activity. After hybridization, the probe/target complexes were bound to avidinylated magnetic beads, which were then collected and used as a source of nucleic acid enriched in RNA component sequences in further cycles of positive selection. The positive selection process is described in

-11-

more detail in Examples 3 and 4, below.

After the third cycle of positive selection, the amplification products were separated by gel electrophoresis, and sections of the gel corresponding to nucleic acids ~200 bp in size were removed. The nucleic acids were then eluted from the gel sections and amplified by PCR. The PCR amplification products were digested with restriction enzyme *Not*I and then inserted by ligation into the *Not*I site of plasmid pBluescriptIISK+, commercially available from Stratagene. The resulting plasmids were transformed into *E. coli* host cells, and individual colonies were isolated and used as a source of nucleic acid for further analysis and DNA sequencing. Individual colonies were grown in the wells of a 96-well microtiter plate, which was then used as a master plate, and blots of DNA from the colonies in the plate were prepared and hybridized to a probe comprising a telomeric repeat sequence and therefore complementary to the RNA component of human telomerase. A number of clones positive by this test were then analyzed by DNA sequencing and a variety of other tests.

These other tests included the following: (1) determination of whether antisense oligonucleotides complementary to the putative RNA component would inhibit telomerase activity in human cell extracts known to contain telomerase (Greider, C.W. and E.H. Blackburn (1989) *supra*); (2) determination of whether PCR primers specific for a putative RNA component clone sequence could be used to amplify a nucleic acid present in a telomerase sample and whether the product observed, if any, would track telomerase activity during purification of telomerase (Greider, C.W. and E.H. Blackburn (1987) *supra*); and (3) determination of whether PCR primers specific for a putative RNA component clone sequence could be used to amplify a nucleic acid present in greater abundance in cell

-12-

extracts from cells in which telomerase activity is known to be high (i.e., tumor cells) than in cell extracts from cells known to produce no or only low amounts of telomerase activity. One clone, designated plasmid pGRN7, produced  
5 results in these tests consistent with the determination that the plasmid comprised cDNA corresponding to the RNA component of human telomerase.

Thus, antisense oligonucleotides corresponding to sequences of the putative RNA component sequence of pGRN7  
10 exhibited inhibition of telomerase activity *in vitro*. Likewise, when telomerase was purified from cell extracts by a process involving (1) DEAE chromatography; (2) Sephadex S300 chromatography; and (3) either glycerol gradient, SP sepharose, or phenyl sepharose separation and  
15 fractions collected, PCR primers specific for the putative RNA component sequence of pGRN7 amplified a nucleic acid of the appropriate size, and the amount of amplification product correlated well with the amount of telomerase activity observed in the fractions collected. Finally,  
20 cell extracts from normal (no detectable telomerase activity) and cancer (telomerase activity present), as well as testis (telomerase activity present), cells showed corresponding amounts of PCR product upon reverse transcription and PCR amplification (RT-PCR) with primers  
25 specific for the putative RNA component comprised in pGRN7. The protocol for the RT-PCR is described in Examples 5 and 6, below.

The above results provided convincing evidence that the RNA component of human telomerase had been cloned.  
30 Therefore, plasmid pGRN7 was then used to isolate a genomic clone for the RNA component from a human cell line, as described in Example 7, below. The genomic clone was identified in and isolated from a genomic library of human DNA inserted into a lambda vector FIXII purchased from  
35 Stratagene. The desired clone comprising the RNA component

-13-

gene sequences contained an ~15 KB insert and was designated clone 28-1. This clone has been deposited with the American Type Culture Collection and is available under the ATCC accession No. 75925. Various restriction fragments were subcloned from this phage and sequenced. The gene has also been localized to the distal end of the q arm of chromosome 3. The sequence information obtained from a *SauIIIA1* restriction enzyme recognition site at one end of the ~15 kb insert to an internal *HindIII* restriction enzyme recognition site, which comprises all of the mature RNA component sequence as well as transcription control elements of the RNA component gene, of lambda clone 28-1 is shown in Figures 1A-1B using the standard deoxyribonucleotide abbreviations and depicted in the 5'-3' direction.

The RNA component sequence begins at base 1459 and ends at base 2017. A variety of transcription control elements can also be identified in the sequence. An A/T Box consensus sequence is found at nucleotides 1438-1444; PSE consensus sequences are found at nucleotides 1238-1250 as well a nucleotides 1406-1414; a CAAT Box consensus sequence is found at nucleotides 1399-1406; an SP1 consensus sequence is found at nucleotides 1354-1359; and a beta-interferon response element consensus sequence is found at nucleotides 1234-1245.

The plasmids described above that were constructed during the cloning of the RNA component of human telomerase and the gene for the RNA component are important aspects of the present invention. These plasmids can be used to produce the RNA component of, as well as the gene for, human telomerase in substantially pure form, yet another important aspect of the present invention. In addition, those of skill in the art recognize that a variety of other plasmids, as well as non-plasmid nucleic acids in substantially pure form, that comprise all or at least a

-14-

portion of the nucleotide sequence of the RNA component of human telomerase are provided by the present invention.

#### The RNA Component of Mouse Telomerase

The cloning of the mouse RNA component of telomerase was initiated by isolating highly purified mouse telomerase fractions using five different column chromatography steps. These active fractions were highly enriched for the RNA component and provided essential ribonucleoenzyme materials for cloning procedures. The cloning procedures are described in detail in Examples 9-13, and the mouse telomerase RNA component gene is shown in Figure 3. The RNA component sequence begins at base 531 and ends at base 1065.

The small RNAs which co-purified with telomerase were sequenced and those that had the template region CTAACCCTAA were identified and targeted as potential RNAs involved in telomerase elongation. The potential RNA generated while cloning the human telomerase RNA component also showed characteristics of a telomerase component. Using the genomic clone of the human RNA component, mouse genomic fragments were identified from a lambda library that hybridized to a human probe at medium stringency. Approximately five genome equivalents were screened with a probe that contained 500 bp of the human telomerase RNA gene. The positive lambda phage were restriction mapped and four were identical to each other. Two positive bands in a *Pst*I digest of the clones which hybridized to the human gene were subcloned and sequenced. The sequence was 64% identical to the 550 nucleotide coding region of the human telomerase RNA indicating that this clone might be the mouse telomerase RNA gene. Outside of coding region, the sequence identity dropped to 45%. The sequence identity in the coding region of the human and putative mouse RNAs is significantly less than that found for other



-15-

small RNA genes between human and mouse. The U-RNA species range from 100% identity for U6 to 85% identity for U7. The mouse and human RNase P RNA and MRP RNAs are 86% and 78% identical respectively. Thus the telomerase RNA is the  
5 least well conserved between human and mouse of any mammalian small functional RNA yet identified. This low level of sequence conservation among telomerase RNAs has also been found in the ciliates. Lingner, et al. (1994) *supra*; Romero, D.P. and E.H. Blackburn, (1991) *supra*.

10 The template region of the human RNA is not absolutely conserved in the mouse sequence. There are 11 nucleotides in the potential template of the human RNA CUAACCCUAAC while there are only 9 possible nucleotides in the mouse RNA CCUAACCCU. This change may be the cause of the  
15 decreased processivity of the mouse enzyme relative to the human enzyme. Prowse, et al. (1993) *supra*.

Due to the low level of sequence conservation between the human and mouse clones, several approaches were used to determine whether the mouse sequence represents the  
20 functional telomerase RNA. First, genomic Southern blots probed at high stringency identified a single band when probed with the potential coding region (data not shown). At lower stringency, several bands were observed; therefore, tests were done to determine if the sequence  
25 obtained was expressed as functional RNA. RT-PCR from total RNA was performed with or without the initial reverse transcriptase step. Using two primers for the initial amplification, followed by a second round of PCR with an internal 'nested' primer, one band with the expected size  
30 of 300 bp was amplified. This band was dependent on the initial reverse transcriptase step indicating it was generated from RNA and not from low levels of contaminating genomic DNA. The sequence of this amplified product  
35 including in the region of the CCTAACCCT template.

-16-

Functional tests indicated that the cloned sequence represented the mouse telomerase RNA component. Investigations of co-purification with telomerase activity (Greider, C.W. and E.H. Blackburn (1987) *supra*) and for antisense oligonucleotide inhibition (Greider, C.W. and E.H. Blackburn (1989) *supra*) showed positive results. Telomerase was purified through chromatography over DEAE agarose, spermine agarose and phenyl sepharose; the telomerase activity was assayed, and RNA was prepared from all of the fractions. Northern analysis showed an RNA of approximately 550 bp was present in the active fractions of these columns. The RNA also co-purified with telomerase activity over a glycerol gradient. The size of the RNA in mouse cells is similar to that found in human cells. (Villeponteau, et al., (1995) in press).

Previous work with *Tetrahymena* telomerase showed that antisense oligonucleotides that cover the template inhibit telomerase and that oligonucleotides with 3' ends adjacent to the template are elongated by telomerase (Greider, C.W. and E.H. Blackburn (1989) *supra*; Lingner, et al. (1994) *supra*). Oligonucleotides directed against the mouse RNA were examined for their effects on both inhibition and elongation of the mouse RNA. Oligonucleotides complementary to the candidate mouse telomerase RNA either covering the template region, MI-2, or hybridizing just 3' to the template MP-1, were tested for their ability to inhibit telomerase or serve as primers. For inhibition assays, each oligonucleotide was pre-incubated with mouse telomerase before the substrate d(TTAGGG), was added. MI-2 which covers 11 nucleotides 3' of the template was an efficient inhibitor of telomerase activity at both 4  $\mu$ M or 10  $\mu$ M. Incubation with MP-1 or two other oligonucleotides that hybridize 3' of the template, MP-2 and MP-3, did not inhibit elongation, indicating that oligonucleotides that

-17-

do not cross the template do not block elongation.

To determine the ability of the antisense oligonucleotides to serve as substrates, each oligonucleotide was added to a telomerase reaction in the  
5 absence of (TTAGGG), primer. The oligonucleotide MP-1, whose 3' end is just adjacent to the 3' RNA template, was elongated by the addition of 8 residues and the addition of these products was RNase sensitive. Two control  
oligonucleotides, MP-2 and MP-3, were not elongated in this  
10 experiment. The addition of 8 nucleotides to MP-1 is consistent with the addition of the template complementary sequence AGGGTTAG onto the primer (see below).

To examine the specificity of the antisense primer inhibition and elongation, three control oligonucleotides  
15 (MI-3, MI-4 and MI-5) were synthesized. MI-4 extended RNA complementarity of MP-1 oligonucleotide through the template region of the RNA. This new oligonucleotide inhibited d(TTAGGG), elongation so that it no longer served as a substrate for elongation although it has telomeric  
20 sequence at the 3' end.

To determine the specificity of MI-2 inhibition, the sequence of the 5' most 9 nucleotides of the oligonucleotide was changed so that it was no longer  
complementary to the RNA. This new oligonucleotide, MI-3,  
25 no longer inhibited d(TTAGGG), elongation; however, it did serve as a substrate for elongation due to the 3' telomeric repeats. The predominant product migrated in the gel at position primer +5 as predicted since the 3' end of the oligonucleotide had the sequence TTAGG. Telomerase is  
30 expected to synthesize the five nucleotides GTTAG onto a primer with this 3' sequence.

As a last control, the 3' most 9 residues of the inhibitory MI-2 oligonucleotide were changed so that the resulting oligonucleotide (designated MI-5), would no

-18-

longer hybridize to the CCUAACCCU template. MI-5 was not a telomerase substrate and did not inhibit d(TTAGGG)<sub>3</sub> elongation. Thus removing the complementarity of the antisense oligonucleotides abolished their ability to  
5 interact with telomerase in a predictable manner. To determine the inhibition efficiency of MI-2 and MI-4, telomerase was pre-incubated with a decreasing concentration of each antisense oligonucleotide prior to the addition of d(TTAGGG)<sub>3</sub>, and then tested for elongation.  
10 Inhibition was complete at 0.2  $\mu$ M for both oligonucleotides. These data show that the cloned RNA gene is a functional component of mouse telomerase.

Both mouse and *Xenopus* telomerase RNAs generate predominately one band during elongation. The position of  
15 the dissociation has been mapped to the first G residue in the sequence TTAG (Mantell, L.L. and C.W. Greider (1994) *EMBO J.* 13:1211-3217; Prowse, et al. (1993) *supra*). To determine the sequence added onto the MP-1 oligonucleotide, dideoxyTTP was substituted for the deoxyTTP in the  
20 elongation reaction. Telomerase reactions were carried out in the presence of <sup>32</sup>P-dGTP, dATP and dTPP or <sup>32</sup>P-dGTP, dATP and ddTPP. Using the primer (TTAGGG)<sub>3</sub> in the presence of dTTP, the typical predominant band at primer +4 was observed (Prowse, et al. (1993) *supra*). When ddTTP was  
25 substituted, all incorporation was abolished due to the incorporation of dTMP before the addition of labeled <sup>32</sup>P-dGTP. Therefore, no labeled products are generated. Using MP-1, the 8 nucleotide labeled product observed with dTTP was reduced to 5 nucleotides in size when ddTTP was added.  
30 Again, this is consistent with the synthesis of AGGGTTAG onto the 3' end of the primer; chain termination with ddT inhibited the addition of the last TAG sequence.

If the entire potential template region of the mouse RNA, CCUAACCCU, were copied, and primer translocation

-19-

occurred at the end of the template, a pause at the second G residue in the repeat d(TTAGGG) would be expected. Lingner, et al. (1994) *supra*; Greider, C.W. and E.H. Blackburn (1989) *supra*. Using permuted sequence primer  
5 oligonucleotides, both the human and the mouse telomerase enzymes pause or dissociate at the first G in the sequence. Prowse, et al. (1993) *supra*; Morin, G.B. (1989) *supra*. These data and the elongation of the antisense  
10 oligonucleotide describe above, show that the 5' most C which is present in the mouse but not the human template region does not serve as a template in the mouse RNA component. This is similar to the 5' most C in the *Styloichia* telomerase RNA template which is apparently also not used as a template position (Lingner, et al.  
15 (1994) *supra*). Similarly, when an additional C residue was added to the 5' most border of the *Tetrahymena* template region, this extra C residue was not incorporated into reaction products (Autexier, C. and C.W. Greider (1994) unpublished data) indicating that there is an active  
20 mechanism to determine the boundaries of the template sequence within the telomerase RNA.

Primer extension and RT-PCR were used to characterize the 5' end of the mouse RNA. Northern analysis showed that the mouse and human telomerase RNAs are similar in size.  
25 Primer extension from total mouse RNA generated two distinct bands, one that mapped 20 nucleotides longer than the human 5' end and one that mapped 15 nucleotides shorter. To determine whether the RNA extends past the position of the mapped human 5' end, an oligonucleotide to  
30 this sequence was used in an RT-PCR reaction. Total RNA was reverse transcribed using random hexamers as primers. This cDNA was then amplified using an internal primer and an 18 nucleotide primer which would hybridize to the 5' most region identified by primer extension. A unique band  
35 of 450 nucleotides was generated and this product was

-20-

further amplified with an internal nested primer, again the correct sized product of 200 nucleotides was generated. The products were cloned and the sequence corresponded to the genomic sequence shown in Figure 4. This indicates  
5 that the RNA starts at the sequence 5' CUCGACC which is designated as +1 in the mouse sequence of Figure 5. It is not yet determined whether the difference in start sites for the human and mouse telomerase RNAs is of functional significance. In Figure 5, the conserved ribonucleotide  
10 residues between the human and mouse RNA sequences are boxed, and the template regions are boxed and highlighted in grey.

The expression of the RNA was assayed in cell lines and tissues where telomerase activity levels vary. Primary  
15 *Mus spretus* fibroblasts lack detectable telomerase activity and show telomere shortening similar to that found in human cells, while immortalized fibroblasts have telomerase activity. Northern analysis showed that immortalized fibroblasts expressed the 550 nucleotide RNA while it was  
20 not detected in primary cells with no telomerase activity. Similarly, the level of RNA present in mouse tissues paralleled the level of telomerase activity. RNA was detected in testes and liver both of which have high levels of telomerase activity. In addition, the RNA level was  
25 high in spleen. Telomerase activity is present in spleen although the relative level of activity compared to liver and testes is not known due to the presence of inhibitors in the crude spleen extracts.

As a general point regarding the nucleic acids and  
30 preparations containing the same of the invention, those of skill in the art recognize that the nucleic acids of the invention include both DNA and RNA molecules, as well as synthetic, non-naturally occurring analogues of the same, and heteropolymers of deoxyribonucleotides,

-21-

ribonucleotides, and/or analogues of either. The particular composition of a nucleic acid or nucleic acid analogue of the invention will depend upon the purpose for which the material will be used and the environment(s) in which the material will be placed. Modified or synthetic, non-naturally occurring nucleotides, have been designed to serve a variety of purposes and to remain stable in a variety of environments, such as those in which nucleases are present, as is well known in the art. Modified or synthetic non-naturally occurring nucleotides, as compared to the naturally occurring nucleotides, as compared to the naturally occurring ribo- or deoxyribonucleotides, may differ with respect to the carbohydrate (sugar), phosphate linkage, or base portions, of the nucleotide, or may even contain a non-nucleotide base (or no base at all) in some cases. See, e.g., Arnold et al., PCT Patent Publication No. WO 89/02439, entitled "Non-nucleotide Linking Reagents for Nucleotide Probes" incorporated herein by reference.

Just as the nucleic acids of the invention can comprise a wide variety of nucleotides, so too can those nucleic acids serve a wide variety of useful functions. RNA probes or primers, especially those comprising about 20 to 200 or more ribonucleotides encoded by DNA encompassing conserved sequences between SEQ ID NO:1 and SEQ ID NO:3 are useful to detect telomerase RNA components in other species, and to inhibit or enhance telomerase activity as described below. DNA probes or primers comprising about 20 to 200 or more deoxyribonucleotides encompassing conserved sequences between SEQ ID NO:1 and SEQ ID NO:3, as well as DNA sequences that hybridize under moderately stringent conditions (Ausubel, et al. (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, NY) to these conserved sequences may also be used for identification, diagnostic, assay and therapeutic purposes. The probes or primers may comprise nucleotides which occur consecutively

-22-

or non-consecutively in naturally-occurring RNA components or DNA encoding these components. In particular, both RNA and DNA probes may be used to identify telomerases and telomerase activity in other mammalian cells. RNA

5 sequences that are substantially homologous to the conserved sequences between SEQ ID NO:1 and SEQ ID NO:3, or that hybridize to these conserved sequences under moderately stringent conditions are also within the scope of this invention.

10 Another especially useful type of nucleic acid of the invention is an antisense oligonucleotide that can be used *in vivo* or *in vitro* to inhibit the activity of human or another mammalian telomerase. Antisense oligonucleotides comprise a specific sequence of from about 10 to about 25  
15 to 200 or more (i.e., large enough to form a stable duplex but small enough, depending on the mode of delivery, to administer *in vivo*, if desired) nucleotides complementary to a specific sequence of nucleotides in the RNA component of a mammalian telomerase. The mechanism of action of such  
20 oligonucleotides can involve binding of the RNA component either to prevent assembly of the functional ribonucleoprotein telomerase or to prevent the RNA component from serving as a template for telomeric DNA synthesis.

25 Illustrative antisense oligonucleotides of the invention that serve to inhibit telomerase activity *in vivo* and/or *in vitro* include the oligonucleotides mentioned above in connection with the tests to determine whether clone pGRN7 comprised the cDNA for the RNA component of  
30 human telomerase. Three such oligonucleotides were synthesized as 2'-O-methyl RNA oligonucleotides and are more resistant to hydrolysis than unmodified RNA oligonucleotides, and, as noted above, were used to demonstrate inhibition of telomerase activity *in vitro*.  
35 The sequence of each of these O-methyl RNA oligonucleotides



-23-

is shown below.

T3 5'-CUCAGUUAGGGUUAGACAAA-3' (SEQ ID NO:6)

P3 5'-CGCCCUUCUCAGUUAGGGUUAG-3' (SEQ ID NO:7)

TA3 5'-GGCGCCUACGCCCUUCUCAGUU-3' (SEQ ID NO:8)

- 5 These oligonucleotides can also be used to inhibit telomerase activity in human cells.

- Those of skill in the art will recognize that the present invention provides a wide variety of antisense oligonucleotides able to inhibit telomerase activity.
- 10 Another useful antisense oligonucleotide of the invention is oligonucleotide Tel-AU, which has the sequence 5'-CAGGCCCACCCTCCGCAACC-3' (SEQ ID NO:9), and which, like any of the antisense oligonucleotides of the invention, can be synthesized using phosphorothioate nucleotides, chiral-
- 15 methyl phosphonates, naturally occurring nucleotides, or mixtures of the same to impart stability and the desired  $T_m$ . Those of skill in the art recognize that a wide variety of modified nucleotide analogues, such as O-methyl ribonucleotides, phosphorothioate nucleotides, and methyl
- 20 phosphonate nucleotides, can be used to produce nucleic acids of the invention with more desired properties (i.e., nuclease-resistant, tighter-binding, etc.) than those produced using naturally occurring nucleotides. Other techniques for rendering oligonucleotides nuclease-
- 25 resistant include those described in PCT patent publication No. 94/12633.

- In addition, to the antisense oligonucleotides of the invention, one can construct oligonucleotides that will bind to duplex nucleic acid either in the folded RNA
- 30 component or in the gene for the RNA component, forming a triple helix-containing or triplex nucleic acid to inhibit telomerase activity. Such oligonucleotides of the invention are constructed using the base-pairing rules of triple helix formation and the nucleotide sequence of the

-24-

RNA component. Such oligonucleotides can block telomerase activity in a number of ways, including by preventing transcription of the telomerase gene or by binding to a duplex region of the RNA component of telomerase in a manner that prevents the RNA component either from forming a functional ribonucleoprotein telomerase or from serving as a template for telomeric DNA synthesis. Typically, and depending on mode of action, the triplex-forming oligonucleotides of the invention comprise a specific sequence of from about 10 to about 25 to 200 or more (i.e., large enough to form a stable triple helix but small enough, depending on the mode of delivery, to administer *in vivo*, if desired) nucleotides "complementary" (in this context, complementary means able to form a stable triple helix) to a specific sequence in the RNA component of telomerase or the gene for the RNA component of telomerase.

In addition to the antisense and triple helix-forming oligonucleotides of the invention, "sense" oligonucleotides identical in sequence to at least a portion of the RNA component of human telomerase or another mammalian telomerase can also be used to inhibit telomerase activity. Oligonucleotides of the invention of this type are characterized in comprising either (1) less than the complete sequence of the RNA component needed to form a functional telomerase enzyme or (2) the complete sequence of the RNA component needed to form a functional telomerase enzyme as well as a substitution or insertion of one or more nucleotides that render the resulting RNA non-functional. In both cases, inhibition of telomerase activity is observed due to the "mutant" RNA component binding the protein components of the telomerase to form an inactive telomerase molecule. The mechanism of action of such oligonucleotides thus involves the assembly of a non-functional ribonucleoprotein telomerase or the prevention of assembly of a functional ribonucleoprotein telomerase.

-25-

Sense oligonucleotides of the invention of this type typically comprise a specific sequence of from about 20, 50, 200, 400, 500, or more nucleotides identical to a specific sequence of nucleotides in the RNA component of a telomerase.

Thus, another oligonucleotide of the invention comprises an altered or mutated sequence of the RNA component of human or another mammalian telomerase. Yu, et al. (1990) *Nature* 344:126, shows that a mutated form of the RNA component of *Tetrahymena* telomerase can be incorporated into the telomerase of *Tetrahymena* cells and that the incorporation has deleterious effects on those cells. Incorporation of mutated forms of the RNA component of human or another mammalian telomerase may have similar effects on human or mammalian cells that otherwise have telomerase activity without affecting normal human cells that do not have telomerase activity. Such mutated forms include those in which the sequence 5'-CTAACCCTA-3' is mutated to 5'-CAAACCCAA-3', 5'-CCAACCCCAA-3', or 5'-CTCACCCTCA-3'. Each of these altered RNA component sequences alters the telomeric repeat units incorporated into the chromosomal DNA, thus affecting chromosome structure and function. Such oligonucleotides can be designed to contain restriction enzyme recognition sites useful in diagnostic methods for the presence of the altered RNA component via restriction enzyme digestion of telomeric DNA or an extended telomerase substrate.

To illustrate this aspect of the invention, site-specific mutagenesis was carried out using a plasmid (designated pGRN33, available from the American Type Culture Collection under ATCC accession No. 75926) that comprises an ~2.5 kb *HindIII*-*SacI* fragment from lambda clone 28-1 (see Example 7, below) as well as the SV40 origin of replication (but no promoter activity). The resulting plasmids, designated pGRN34 (comprising 5'-

CAACCCCAA-3'), pGRN36 (comprising 5'-CCAACCCCAA-3'), and pGRN37 (comprising 5'-CTCACCCCTCA-3'), were transformed into eukaryotic host cells (a 293-derived cell line expressing SV40 large T antigen), and telomerase assays were conducted using cell extracts from the transformants.

The assays showed that the telomerase activity in the cells resulted in the formation of nucleic acids comprising the altered sequences, indicating that the genomic clone comprised a functional RNA component gene and that the plasmids comprised an altered but functional RNA component gene. These results illustrate how the present invention provides recombinant telomerase preparations and methods for producing such preparations. The present invention provides a recombinant human or mammalian telomerase in functional association with a recombinant RNA component of the invention. Such recombinant RNA component molecules of the invention include those that differ from naturally occurring RNA component molecules by one or more base substitutions, deletions, or insertions, as well as RNA component molecules identical to a naturally occurring RNA component molecule that are produced in recombinant host cells. The method for producing such recombinant telomerase molecules comprises transforming a eukaryotic host cell that expresses the protein components of telomerase with a recombinant expression vector under conditions such that the protein components and RNA components are expressed and assemble to form an active telomerase molecule capable of adding sequences (not necessarily the same sequence added by native telomerase) to telomeres of chromosomal DNA. Other useful embodiments of such recombinant DNA expression vectors (or plasmids) include plasmids that comprise the gene for the RNA component of human telomerase with a deletion, insertion, or other modification that renders the gene non-functional. Such plasmids are especially useful for gene therapy to

-27-

"knock-out" the endogenous RNA component gene, although a highly efficient transformation and recombination system is required, to render the treated cells irreversibly mortal.

Other oligonucleotides of the invention called

5 "ribozymes" can also be used to inhibit telomerase activity. Unlike the antisense and other oligonucleotides described above, which bind to an RNA, a DNA, or a telomerase protein component, a ribozyme not only binds but also specifically cleaves and thereby potentially

10 inactivates a target RNA, such as the RNA component of human telomerase. Such a ribozyme can comprise 5'- and 3'- terminal sequences complementary to the telomerase RNA. Depending on the site of cleavage, a ribozyme can render the telomerase enzyme inactive. See PCT patent publication

15 No. 93/23572, supra. Those in the art upon review of the RNA sequence of the human or mouse telomerase RNA component will note that several useful ribozyme target sites are present and susceptible to cleavage by, for example, a hammerhead motif ribozyme. Illustrative human ribozymes of

20 the invention of this type include the ribozymes below, which are RNA molecules having the sequences indicated:

1: 5'-UAGGGUUACUGAUGAGUCCGUGAGGACGAAACAAAAAU-3' (SEQ ID NO:10)

2: 5'-UUAGGGUCUGAUGAGUCCGUGAGGACGAAAGACAAAA-3' (SEQ ID NO:11)

3: 5'-UCUCAGUCUGAUGAGUCCGUGAGGACGAAAGGGUUA-3' (SEQ ID NO:12)

4: 5'-CCCGAGACUGAUGAGUCCGUGAGGACGAAACCCGCG-3' (SEQ ID NO:13).

30 Other optimum target sites for ribozyme-mediated inhibition of telomerase activity can be determined as described by Sullivan, et al., PCT patent publication No. 94/02595 and Draper, et al., PCT publication No. 93/23569, both

-28-

incorporated herein by reference. As described by Hu, et al., PCT patent publication No. 94/03596, incorporated herein by reference, antisense and ribozyme functions can be combined in a single oligonucleotide. Moreover,  
5 ribozymes can comprise one or more modified nucleotides or modified linkages between nucleotides, as described above in conjunction with the description of illustrative antisense oligonucleotides of the invention.

Thus, the invention provides a wide variety of  
10 oligonucleotides to inhibit telomerase activity. Such oligonucleotides can be used in the therapeutic methods of the invention for treating disease, which methods comprise administering to a patient a therapeutically effective dose of a telomerase inhibitor or activator of the invention.  
15 One can measure telomerase inhibition or activation to determine the amount of an agent that should be delivered in a therapeutically effective dose using the assay protocols described in the copending U.S. patent applications and PCT patent publication No. 93/23572 noted  
20 above. As noted in those application and discussed above, inhibition of telomerase activity renders an immortal cell mortal, while activation of telomerase activity can increase the replicative lifespan of a cell. Telomerase inhibition therapy is an effective treatment against  
25 cancers involving the uncontrolled growth of immortal cells, and telomerase activation is an effective treatment to prevent cell senescence. Delivery of agents that inhibit or block telomerase activity, such as an antisense oligonucleotide, a triple helix-forming oligonucleotide, a  
30 ribozyme, or a plasmid that drives expression of a mutant RNA component of telomerase can prevent telomerase action and ultimately leads to cell senescence and cell death of treated cells.

In addition, the present invention provides  
35 therapeutic methods that ensure that normal cells remain

mortal; for instance, the RNA component can be modified using standard genetic engineering procedures to delete all or a portion of a natural gene encoding the component (e.g., by *in vitro* mutagenesis) by genetic recombination.

5 Such cells will then be irreversibly mortal. This procedure is useful in gene therapy, where normal cells modified to contain expression plasmids are introduced into a patient, and one wants to ensure cancerous cells are not introduced or, if such cells are introduced, then those

10 cells have been rendered irreversibly mortal.

Because telomerase is active only in tumor, germline, and certain stem cells of the hematopoietic system in humans, other normal cells are not affected by telomerase inhibition therapy. Steps can also be taken to avoid

15 contact of the telomerase inhibitor with germline or stem cells, although this may not be essential. For instance, because germline cells express telomerase activity, inhibition of telomerase may negatively impact spermatogenesis and sperm viability, suggesting that

20 telomerase inhibitors may be effective contraceptives or sterilization agents. This contraceptive effect may not be desired, however by a patient receiving a telomerase inhibitor of the invention for treatment of cancer. In such cases, one can deliver a telomerase inhibitor of the

25 invention in a manner that ensures the inhibitor will only be produced during the period of therapy, such that the negative impact on germline cells is only transient.

Other therapeutic methods of the invention employ the telomerase RNA nucleic acid of the invention to stimulate

30 telomerase activity and to extend replicative cell life span. These methods can be carried out by delivering to a cell a functional recombinant telomerase ribonucleoprotein of the invention to the cell. For instance, the ribonucleoprotein can be delivered to a cell in a liposome,

35 or the gene for the RNA component of human telomerase (or a

-30-

recombinant gene with different regulatory elements) can be used in a eukaryotic expression plasmid (with or without sequences coding for the expression of the protein components of telomerase) to activate telomerase activity  
5 in various normal human cells that otherwise lack detectable telomerase activity due to low levels of expression of the RNA component or a protein component of telomerase. If the telomerase RNA component is not sufficient to stimulate telomerase activity, then the RNA  
10 component can be transfected along with genes expressing the protein components of telomerase to stimulate telomerase activity. Thus, the invention provides methods for treating a condition associated with the telomerase activity within a cell or group of cells by contacting the  
15 cell(s) with a therapeutically effective amount of an agent that alters telomerase activity in that cell.

Cells that incorporate extra copies of the telomerase RNA gene can exhibit an increase in telomerase activity and an associated extended replicative life span. Such therapy  
20 can be carried out *ex vivo* on cells for subsequent introduction into a host or can be carried out *in vivo*. The advantages of stabilizing or increasing telomere length by adding exogenous telomerase genes *ex vivo* to normal diploid cells include: telomere stabilization can arrest  
25 cellular senescence and allow potentially unlimited amplification of the cells; and normal diploid cells with an extended life span can be cultured *in vitro* for drug testing, virus manufacture, or other useful purposes. Moreover, *ex vivo* amplified stem cells of various types can  
30 be used in cell therapy for particular diseases, as noted above.

Telomere stabilization can also suppress cancer incidence in replicating cells by preventing telomeres from becoming critically short as cells near crisis. During  
35 crisis, massive genomic instability is generated as the



protective effect of the telomeric cap is lost. The "genetic deck" is reshuffled, and almost all cells die. The rare cells that emerge from this process are typically aneuploid with many gene rearrangements and end up  
5 reestablishing stability in their telomeres by expressing telomerase. If crisis can be prevented by keeping telomeres long, then the genomic instability associated with crisis can also be prevented, limiting the chances than an individual cell will suffer the required number of  
10 genetic mutations needed to spawn a metastatic cancer.

Cells that can be targeted for telomerase gene therapy (therapy involving increasing the telomerase activity of a target cell) in humans include but are not limited to hematopoietic stem cells (AIDS and post-chemotherapy),  
15 vascular endothelial cells (cardiac and cerebral vascular disease), skin fibroblasts and basal skin keratinocytes (wound healing and burns), chondrocytes (arthritis), brain astrocytes and microglial cells (Alzheimer's Disease), osteoblasts (osteoporosis), retinal cells (eye diseases),  
20 and pancreatic islet cells (Type I diabetes).

Typically, the therapeutic methods of the invention involve the administration of an oligonucleotide or drug that functions to inhibit or stimulate telomerase activity under *in vivo* physiological conditions and will be stable  
25 under those conditions. As noted above, modified nucleic acids may be useful in imparting such stability, as well as for ensuring delivery of the oligonucleotide to the desired tissue, organ, or cell. Methods useful for delivery of oligonucleotides for therapeutic purposes are described in  
30 Inouye et al., U.S. Patent 5,272,065, incorporated herein by reference.

While oligonucleotides can be delivered directly as a drug in a suitable pharmaceutical formulation, one can also deliver oligonucleotides using gene therapy and recombinant  
35 DNA expression plasmids of the invention. One such

-32-

illustrative plasmid is described in Example 8, below. In general, such plasmids will comprise a promoter and, optionally, an enhancer (separate from any contained within the promoter sequences) that serve to drive transcription of an oligoribonucleotide, as well as other regulatory elements that provide for episomal maintenance or chromosomal integration and for high-level transcription, if desired. Adenovirus-based vectors are often used for gene therapy and are suitable for use in conjunction with the reagents and methods of the present invention. See PCT patent publication Nos. 94/12650; 94/12649; and 94/12629. Useful promoters for such purposes include the metallothionein promoter, the constitutive adenovirus major late promoter, the dexamethasone-inducible MMTV promoter, the SV40 promoter, the MRP polIII promoter, the constitutive MPSV promoter, the tetracycline-inducible CMV promoter (such as the human immediate-early CMV promoter), and the constitutive CMV promoter. A plasmid useful for gene therapy can comprise other functional elements, such as selectable markers, identification regions, and other genes. Recombinant DNA expression plasmids can also be used to prepare the oligonucleotides of the invention for delivery by means other than by gene therapy, although it may be more economical to make short oligonucleotides by *in vitro* chemical synthesis.

In related aspects, the invention features pharmaceutical compositions including a therapeutically effective amount of a telomerase inhibitor or telomerase activator of the invention. Pharmaceutical compositions of telomerase inhibitors of the invention include a mutant RNA component of human or another mammalian telomerase, an antisense oligonucleotide or triple helix-forming oligonucleotide that binds the RNA component or the gene for the same of human or another mammalian telomerase, or a ribozyme able to cleave the RNA component of human or

another mammalian telomerase, or combinations of the same or other pharmaceuticals in a pharmaceutically acceptable carrier or salt. Other pharmaceutical compositions of the invention comprise a telomerase activator preparation, such as purified human telomerase or mRNA for the protein components of telomerase and the RNA component of telomerase, and are used to treat senescence-related disease. The therapeutic agent can be provided in a formulation suitable for parenteral, nasal, oral, or other mode of administration. See PCT patent publication No. 93/23572, *supra*.

The present invention provides diagnostic methods and reagents in addition to the pharmaceutical formulations and therapeutic methods described above. The invention provides diagnostic methods for determining the level, amount, or presence of the RNA component of telomerase, telomerase, or telomerase activity in a cell, cell population, or tissue sample. In a related aspect, the present invention provides useful reagents for such methods, optionally packaged into kit form together with instruction for using the kit to practice the diagnostic methods.

In addition, probes or primers that bind specifically to the RNA component of a telomerase (or either strand of the gene for the same) can be used in diagnostic methods to detect the presence of telomerase nucleic acid in a sample. Primers and probes are oligonucleotides that are complementary, and so will bind, to a target nucleic acid. Although primers and probes can differ in sequence and length, the primary differentiating factor is one of function: primers serve to initiate DNA synthesis, as in PCR amplification, while probes are typically used only to bind to a target nucleic acid. Typical lengths for a primer or probe can range from 8 to 20 to 30 or more nucleotides. A primer or probe can also be labeled to

-34-

facilitate detection (i.e., radioactive or fluorescent molecules are typically used for this purpose) or purification/separation (i.e., biotin or avidin is often used for this purpose).

- 5           An especially preferred diagnostic method of the invention involves the detection of telomerase RNA component sequences in cell or tissue samples taken from patients suspected to be at risk for cancer. Such methods will typically involve binding a labelled probe or primer  
10   to an RNA component sequence under conditions such that only perfectly matched (complementary) sequences bind (hybridize) to one another. Detection of labelled material bound to RNA in the sample can correlate with the presence of telomerase activity and the presence of cancer cells.  
15   The diagnostic methods of the invention may be especially useful in detecting the presence of telomerase activity in tissue biopsies and histological sections in which the method is carried out in situ, typically after amplification of telomerase RNA component using specific  
20   PCR primers of the invention.

- Depending on the length and intended function of the primer, probe, or other nucleic acid comprising sequences from the RNA component of a telomerase, expression plasmids of the invention may be useful. For instance, recombinant  
25   production of the full-length RNA component of human telomerase can be carried out using a recombinant DNA expression plasmid of the invention that comprises a nucleic acid comprising the nucleotide sequence of the RNA component positioned for transcription under the control of  
30   a suitable promoter. Host cells for such plasmids can be either prokaryotic or eukaryotic, and the promoter, as well as the other regulatory elements and selectable markers chosen for incorporation into the expression plasmid will depend upon the host cell used for production.

- 35           The intact RNA components gene, i.e., the promoter,

which includes any regulatory sequences in the 5'-region of the gene, and RNA component coding region, can be used to express the RNA component in human cells, including human cells that have been immortalized by viral transformation or cancer. The promoter of the RNA component gene may be regulated, however, and for this and other reasons, one may want to express the RNA component under the control of a different promoter. On the other hand, the promoter of the RNA component gene can be used independently of the RNA component coding sequence to express other coding sequences of interest. For instance, one could study the transcriptional regulation of the RNA component gene by fusing the promoter of the RNA component gene to a coding sequence for a "reporter" coding sequence, such as the coding sequence for beta-galactosidase or another enzyme or protein the expression of which can be readily monitored. Thus, the promoter and other regulatory elements of the gene for the RNA component of human telomerase can be used not only to express the RNA component but also protein components of human telomerase, antisense or other oligonucleotides, as well as other gene products of interest in human cells. Expression plasmids comprising the intact gene for the RNA component of human telomerase can be especially useful for a variety of purposes, including gene therapy. Those of skill in the art recognize that a wide variety of expression plasmids can be used to produce useful nucleic acids of the invention and that the term "plasmid", as used herein, refers to any type of nucleic acid (from a phage, virus, chromosome, etc.) that can be used to carry specific genetic information into a host cell and maintain that information for a period of time.

As indicated by the foregoing description, access to purified nucleic acids comprising or encoding the sequence of the RNA component of a telomerase provides valuable

diagnostic and therapeutic methods and reagents, as well as other important benefits. One important benefit of the present invention is that the methods and reagents of the invention can be used to isolate the RNA component and  
5 genes for the RNA component of telomerase from any other mammalian species that has an RNA component substantially homologous to the human, mouse, rat, Chinese hamster or bovine coding region of the RNA component of the present invention. The phrase "substantially homologous" refers to  
10 that degree of homology required for specific hybridization of an oligonucleotide or nucleic acid sequence of the human, mouse, rat, Chinese hamster or bovine RNA component to a nucleic acid sequence of an RNA component sequence of another mammalian species. Given such substantial  
15 homology, those of ordinary skill in the art can use the nucleic acids and oligonucleotide primers and probes of the invention to identify and isolate substantially homologous sequences. Further, these conserved sequences can constitute a framework from which RNA components can be  
20 synthesized and modified to assess the effects of nucleotide changes on secondary structure and function, as well as to construct novel or chimeric mammalian RNA components for diagnostic and therapeutic purposes. Thus DNA that encompasses 5 or more of the conserved sequences  
25 between SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:43 and SEQ ID NO:44, and RNA encoded by or substantially homologous to such DNA is within the scope of this invention.

RNA probes and primers, especially those comprising  
30 about 20 to 200 or more ribonucleotides encoded by DNA encompassing conserved sequences between SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:43 and SEQ ID NO:44, are useful to detect telomerase RNA components in other species, and to inhibit or enhance telomerase activity.  
35 DNA probes and primers, especially those comprising about

-37-

20 to 200 or more nucleotides encompassing conserved sequences between SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:43 and SEQ ID NO:44, as well as DNA sequences that hybridize under moderately stringent conditions to these conserved sequences may also be used for identification, diagnostic, assay and therapeutic purposes. The probes or primers may comprise nucleotides which occur consecutively or non-consecutively in naturally-occurring RNA components or DNA encoding the components. Both RNA and DNA probes may be used to identify telomerases and telomerase activity in other mammalian cells, and RNA sequences that are substantially homologous to the conserved sequences between SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:43 and SEQ ID NO:44, or that hybridize to these conserved sequences under moderately stringent conditions are also within the scope of this invention.

For instance, one can probe a genomic or cDNA library to detect homologous sequences. One can also use primers corresponding to regions of the RNA component sequence and PCR amplification under low or moderate stringency conditions to amplify a specific homologous nucleic acid sequence from preparations of RNA or DNA from a mammalian species. By using these and other similar techniques, those of ordinary skill can readily isolate not only variant RNA component nucleic acid from human or mouse cells but also homologous RNA component nucleic acids from other mammalian cells, such as cells from primates, from mammals of veterinary interest, i.e., sheep, horses, dogs, and cats, and from other rodents. An example of this application, wherein mouse RNA component is isolated and sequenced, has already been described. Example 15 also illustrates how such methodology has been used to identify and isolate the sequence of the rat, Chinese hamster and bovine RNA components and RNA component sequences of primates. Further, probes or primers that comprise

-38-

nucleotide sequences encoding conserved ribonucleotides between the human, mouse, rat, Chinese hamster, and bovine telomerase RNA components (see Figure 7A-7B) are especially useful for this purpose because they are most likely to be  
5 conserved and constitute part of the RNA component in other mammals.

The reagents of the present invention also allow the cloning and isolation of nucleic acids encoding the protein components of human as well as other mammalian telomerase  
10 enzymes, which have not previously been available. Access to such nucleic acids provide complementary benefits to those provided by the nucleic acids comprising nucleic acid sequences of the RNA component of human or other mammalian telomerases. For instance, and as noted above, the  
15 therapeutic benefits of the present invention can be enhanced, in some instances, by use of purified preparations of the protein components of human telomerase and by access to nucleic acids encoding the same. The nucleic acids of the invention that encode the RNA  
20 component of human telomerase can be used to isolate the nucleic acid encoding the protein components of human telomerase, allowing access to such benefits. Thus, the invention provides methods for isolating and purifying the protein components of human telomerase, as well as for  
25 identifying and isolating nucleic acids encoding the protein components of human telomerase. In related aspects, the present invention provides purified human telomerase, purified nucleic acids that encode the protein components of human telomerase, and recombinant expression  
30 plasmids for the protein components of human telomerase. The invention also provides pharmaceutical compositions comprising as an active ingredient either the protein components of human telomerase or a nucleic acid that either encodes those protein components or interacts with  
35 nucleic acids that encode those protein components, such as



-39-

antisense oligonucleotides, triple helix-forming oligonucleotides, ribozymes, or recombinant DNA expression plasmids for any of the foregoing.

The cloned RNA component of human or other mammalian telomerases can be used to identify and clone nucleic acids encoding the protein components of the ribonucleoprotein telomerase enzyme. Several different methods can be employed to achieve identification and cloning of the protein components. For instance, one can use affinity capture of the enzyme or partially denatured enzyme using as a affinity ligand either (1) nucleotide sequences complementary to the RNA component to bind to the RNA component of the intact enzyme; or (2) the RNA component to bind the protein components of a partially or fully denatured enzyme. The ligand can be affixed to a solid support or chemically modified (e.g., biotinylated) for subsequent immobilization on the support. Exposure of cell extracts containing human telomerase, followed by washing and elution of the telomerase enzyme bound to the support, provides a highly purified preparation of the telomerase enzyme. The protein components can then be optionally purified further or directly analyzed by protein sequencing. The protein sequence determined can be used to prepare primers and probes for cloning the cDNA or identifying a clone in a genomic bank comprising nucleic acids that encode a protein component of telomerase.

Affinity capture of telomerase utilizing an engineered RNA component can also be conducted using *in vitro* transcribed telomerase RNA and a system for the reconstitution of telomerase enzyme activity. See Autexier, C. and C.W. Greider (1994) *Genes & Development* 8:563-575, incorporated herein by reference. The RNA is engineered to contain a tag, similar to epitope tagging of proteins. The tag can be an RNA sequence to which a tightly binding ligand is available, e.g., an RNA sequence-

-40-

specific antibody, a sequence-specific nucleic acid binding protein, or an organic dye that binds tightly to a specific RNA sequence. The tolerance of telomerase for the tag sequence and position can be tested using standard methods.

- 5 Synthesis of the altered RNA component and the reconstitution step of this method can also be carried on *in vivo*. Affinity capture using the immobilized ligand for the RNA tag can then be used to isolate the enzyme.

- Expression screening can also be used to isolate the  
10 protein components of the telomerase enzyme. In this method, cDNA expression libraries can be screened with labeled telomerase RNA, and cDNAs encoding proteins that bind specifically to telomerase RNA can be identified. A molecular genetic approach using translational inhibition  
15 can also be used to isolate nucleic acids encoding the protein components of the telomerase enzyme. In this method, telomerase RNA sequences will be fused upstream of a selectable marker. When expressed in a suitable system, the selectable marker will be functional. When cDNA  
20 encoding a telomerase RNA binding protein is expressed, the protein will bind to its recognition sequence thereby blocking translation of the selectable marker, thus allowing for identification of the clone encoding the protein. In other embodiments of this method, the blocked  
25 translation of the selectable marker will allow transformed cells to grow. Other systems that can be employed include the "interaction trap system" described in PCT patent publication No. WO 94/10300; the "one-hybrid" system described in Li and Herskowitz (1993) *Science* 262:1870-  
30 1874, and Zervos, et al. (1993) *Cell* 72:223-232; and the "two-hybrid" system commercially available from Clontech.

- Telomerase RNA binding or telomerase activity assays for detection of specific binding proteins and activity can be used to facilitate the purification of the telomerase  
35 enzyme and the identification of nucleic acids that encode

-41-

the protein components of the enzyme. For example, nucleic acids comprising RNA component sequences can be used as affinity reagents to isolate, identify, and purify peptides, proteins or other compounds that bind specifically to a sequence contained within the RNA component, such as the protein component of human telomerase. Several different formats are available, including gel shift, filter binding, footprinting, Northwestern (RNA probe of protein blot), and photocrosslinking, to detect such binding and isolate the components that bind specifically to the RNA component. These assays can be used to identify binding proteins, to track purification of binding proteins, to characterize the RNA binding sites, to determine the molecular size of binding proteins, to label proteins for preparative isolation, and for subsequent immunization of animals for antibody generation to obtain antibodies for use in isolating the protein or identifying a nucleic acid encoding the protein in a coupled transcription/translation system.

The mouse, rat, or Chinese hamster RNA components have many additional uses. Like the human RNA component, they can be used to prepare transgenic animals of great value for screening and testing of pharmaceuticals that regulate telomerase activity.

For instance, by using a plasmid, one can "knock out" the RNA component gene or replace the natural RNA component gene with a recombinant inducible gene in a *Mus musculus* embryonic stem cell and then generate a transgenic mouse that will be useful as a model or test system for the study of cancer, or age- or senescence-related disease. The generation of mice and mouse cells lacking telomerase makes it possible to determine the effects of telomerase inhibitors directly. In addition, the toxicity of telomerase inhibitors can be assessed in an animal model

-42-

where the specific target has been removed. Thus, any side effects of such inhibitors will be revealed in the mouse model.

Initially a knockout mouse is generated with one of the two telomerase alleles deleted. As an example of a knockout plasmid that could be used for this task, a plasmid vector has been constructed (Figure 6) using standard cloning procedures. Sambrook, et al. (1989) *supra*. In this plasmid, the entire telomerase RNA gene has been eliminated and replaced by the bacterial neomycin gene (neo). The restriction map of the mouse telomerase RNA genomic region is shown in Figure 6, as well as the sections that were cloned into the knockout vector. This plasmid can be used to generate knockout mice from a number of *Mus musculus* ES cell strains.

Mouse model systems can also be used to study telomerase regulation and telomere length in mammals. Similar to human cells, mouse fibroblasts show no telomerase activity during growth while telomere length decreases until the culture passes through crisis when telomerase activity is detected as the telomere length stabilizes. Furthermore, telomere lengths from tissues of individual adult mice differ between tissues. For example, testes telomere length is significantly longer than in other tissues, suggesting that a developmentally-regulated telomere length increase may occur after birth. Thus the mouse offers an excellent system in which to directly test the role of telomerase in aging and immortalization because the effects of altered telomerase on both cell viability and organismal development can be determined *in vivo*.

The same or another mammalian system can be used to test the effects of therapeutic and pharmaceutical compounds on telomerase activity. Anti-telomerase compositions, including antibodies, directed towards telomerase activity in tumors can be screened for

-43-

efficacies and side effects.

As will be apparent to those of skill in the art upon reading of this disclosure, the present invention provides valuable reagents relating to human or mammalian telomerases, as well as a variety of useful therapeutic and diagnostic methods, and model systems. The above description of necessity provides a limited sample of such methods, which should not be construed as limiting the scope of the invention. Other features and advantages of the invention will be apparent from the following examples and claims.

The following examples describe specific aspects of the invention to illustrate the invention and provide a description of the methods used to isolate and identify the RNA component of human, mouse, rat, Chinese hamster and bovine telomerase for those of skill in the art. The examples should not be construed as limiting the invention, as the examples merely provide specific methodology useful in understanding and practice of the invention.

20

#### Example 1

##### Preparation of PCT-amplifiable cDNA

RNA was obtained from 293 cells by guanidine-thiocyanate extraction of from purified telomerase fractions by phenol/chloroform extractions. The total RNA from 293 cells was size fractionated on a 2% agarose gel, and the RNA below 500 bp was isolated.

First strand cDNA synthesis was performed with Superscript™ II reverse transcriptase obtained from Bethesda Research Laboratories (BRL). About 0.5 to 1.0 µg RNA was mixed with about 40 ng of random primer (6 mer) in water at a total volume of 11 µl. The solution was heated for 10 min. at 95°C and then cooled on ice for 5-10 min.

-44-

The denatured nucleic acid was collected by centrifugation. The denatured RNA and primer mixture were then resuspended by adding, in the order shown: 4  $\mu$ l 5x 1st strand synthesis buffer; 2  $\mu$ l 0.1 M dithiothreitol (DTT); 1  $\mu$ l RNAsin (Pharmacia); and 1  $\mu$ l dNTP (0.125 mM each for 0.5 mM total concentration). The reaction mixture was incubated at 42°C for 1 min., and then, 1  $\mu$ l (200 units) of Superscript™ II RTase (BRL) was added and mixed into the reaction, which was then incubated for 60 min. at 42°C.

10 The resulting reaction mixture, containing the newly synthesized cDNA was placed on ice until second strand synthesis was performed.

Second strand cDNA synthesis was performed as follows: About 20  $\mu$ l of the reaction mixture from the first strand cDNA synthesis reaction mixture (from above) was mixed with, in the order shown, the following components: 111.1  $\mu$ l of water; 16  $\mu$ l of 10x *E. coli* DNA ligase buffer; 3  $\mu$ l of dNTP (2.5 mM each stock); 1.5  $\mu$ l of *E. coli* DNA ligase (15 units from BRL); 7.7  $\mu$ l of *E. coli* DNA polymerase (40 units from Pharmacia); and 0.7  $\mu$ l of *E. coli* RNase H (BRL). The resulting solution was gently mixed and incubated for 2 hours at 16°C, at which time 1  $\mu$ l (10 units) of T4 DNA polymerase was added to the reaction tube and incubation continued for 5 min. at the same temperature (16°C). The reaction was stopped, and the nucleic acid was collected by extracting the reaction with phenol/chloroform twice, precipitating the nucleic acid with ethanol, and centrifuging the reaction mixture to pellet the nucleic acid.

30 The cDNA pellet collected by centrifugation was resuspended in 20  $\mu$ l of TE buffer and ligated to a double-stranded oligonucleotide called "NotAB" composed of two oligonucleotides (NH2 is an amino blocking group):

NotA: 5'-pATAGCGGCCGCAAGAATTCA-NH2 (SEQ ID NO:14)

-45-

NotB: 5'-TGAATTCTTGCGGCCGCTAT-3' (SEQ ID NO:15)

The double-stranded oligonucleotide was made by mixing 50  $\mu$  of NotA oligonucleotide (100 pmol) with 50  $\mu$ l of NotB oligonucleotide (100 pmol) in 46.25  $\mu$ l of water, heating the resulting solution for 5 min. at 95°C, and adding 3.75  $\mu$ l of 20x SSC buffer while the solution was still hot. The tube containing the mixture was then placed in a beaker containing hot water (at a temperature of about 70 to 75°C), the temperature of which was allowed to drop slowly to below 15°C, so that the two oligonucleotides could hybridize to form the double-stranded oligonucleotide NotAB. The resulting nucleic acid was collected by precipitation and centrifugation.

The double-stranded NotAB oligonucleotide was resuspended in about 30  $\mu$ l TE buffer and then ligated to the cDNA in a reaction mixture containing 10  $\mu$ l of the cDNA preparation described above, about 50 pmol (calculated by OD260) of NotAB; 2  $\mu$ l of 10x T4 DNA ligase buffer; 1.2  $\mu$ l of T4 DNA ligase; 0.2  $\mu$ l of 10 mM ATP; and water in a total volume of 20  $\mu$ l by incubating the reaction mixture at 16°C overnight. The reaction was then heat-inactivated by heating the reaction mixture for 10 min. at 65°C. About 1 to 2  $\mu$ l of the resulting mixture was typically used for PCR amplification; one can amplify the ligation mixture for 10 to 15 cycles (94°C, 45 seconds; 60°C, 45 seconds; and 72°C, 1.5 min.) and save as a stock, as described in Example 2.

### Example 2

#### PCR amplification of cDNA

The cDNA was routinely amplified by preparing an amplification reaction mixture composed of 5  $\mu$ l of 10x PCR buffer (500 mM KCL; 100 mM Tris, pH=8.3; and 20 mM MgCl<sub>2</sub>; 5-8  $\mu$ l of dNTP (2.5 mM each); 1  $\mu$ l of Taq polymerase (Boehringer-Mannheim); 0.1  $\mu$ l of gene 32 protein

-46-

(Boehringer-Mannheim); 6  $\mu$ l of Not B primer (20  $\mu$ M stock); 2  $\mu$ l of the cDNA (prepared as described in Example 1), and water to 50  $\mu$ l. This mixture was then overlaid with 50 to 100  $\mu$ l of mineral oil, and PCR amplification was performed for 10 to 15 cycles of 94°C, 45 seconds; 60°C, 45 seconds; and 72°C, 1.5 min. After amplification, the reaction mixture was extracted with phenol/chloroform, and the amplified nucleic acid was precipitated with ethanol and collected by centrifugation. The precipitate was then dissolved in 100  $\mu$ l of TE buffer to prepare a stock solution.

### Example 3

#### PCR amplification for cyclic selection

To make PCR product for cyclic selection, about 1  $\mu$ l of a stock solution prepared as described in Example 2 was amplified in 50  $\mu$ l of PCR reaction mixture prepared as described in Example 2, except that 21-24 cycles of primer annealing, extension, and denaturation of product were conducted. After amplification, reaction mixtures were extracted with phenol/chloroform, precipitated with ethanol, and collected by centrifugation. Product yield was estimated by staining with ethidium bromide after agarose gel electrophoresis of a small aliquot of the reaction mixture. Typically, about 2  $\mu$ g of the nucleic acid product were used for cyclic selection.

After cyclic selection, described in Example 4, about 1 to 2  $\mu$ l of the selected "pull-down" products (out of a total volume of 20  $\mu$ l) were PCR amplified as described in Example 2 for 22 cycles, precipitated with ethanol, and collected by centrifugation in preparation for further cyclic selection.

### Example 4



Positive selection of PCT-amplified cDNA

For the positive selection step of the cyclic selection process used to clone the RNA component of human telomerase, about 2  $\mu$ g of the PCR-amplified cDNA were  
5 diluted into 25  $\mu$ l of TE buffer and then mixed with 1.25  $\mu$ l of 20X SSC and the resulting solution heated to 95  $^{\circ}$ C for 3 min. The temperature was lowered to 60 $^{\circ}$ C for 5 min., and one  $\mu$ l (0.1  $\mu$ g/ $\mu$ l) of the R2 or R4 biotinylated probe was added. The sequences of these probes are shown below. The  
10 probes are O-methyl-RNA probes, so U is O-methyl-uridine, A is O-methyl-riboadenine, G is O-methyl-riboguanine, and I is inosine.

R2: 5'-UUAGGGUUAGII-biotin

R4: 5'-AUUGGGUUAUII-biotin

15 The R2 probe is specific for the telomere repeat, and the R4 probe is specific for RNase P, which was used to track the effectiveness and efficiency of the cyclic selection process. By carrying out a cyclic selection simultaneously but separately for RNase P RNA, a molecule of known  
20 sequence, one can have greater confidence that the cyclic selection process is functioning properly with respect to the molecule of interest, in this case the RNA component of human telomerase.

After either the R2 or R4 probe was added to the  
25 mixture at 65 $^{\circ}$ C, the temperature of the hybridization reaction mixture was lowered to 30 $^{\circ}$ C by incubating the mixture at that temperature for 5 min., and then the reaction mixtures were further lowered to a temperature of 14 $^{\circ}$ C by incubating at that temperature for 60 min.

30 Finally, the mixture was incubated at 4 $^{\circ}$ C for 2-12 hours.

The entire hybridization reaction mixture for each sample (R2 or R4) was added to 400  $\mu$ l of 0.5X SSC at 4 $^{\circ}$ C

-48-

and then added to a tube of ice-cold magnetic beads, which were purchased from Promega and pre-washed four times with 0.5X SSC before use. The resulting mixture was incubated 30 min. at 4°C to ensure complete binding to the magnetic beads. Each reaction tube was then incubated briefly at room temperature on the magnetic stand (Promega) to pull down the beads. The beads were resuspended in cold 0.5X SSC (600  $\mu$ l) and placed (in a tube) on ice. The samples were washed three more times with 0.5X SSC in this manner. Nucleic acid was eluted from the beads by resuspending the beads in 100  $\mu$ l of water and incubating for 2 min. at 65°C before placing the beads back on the magnetic stand for collection. This process was repeated three more times; the last time, the resuspended beads were incubated for 5 min. at 65°C before placing the beads on the magnetic stand for collection. All of the 100  $\mu$ l supernatants (for each sample) were pooled and dried down to 20  $\mu$ l in a SpeedVac™ centrifuge. The recovered DNA was then PCR amplified for another round of amplification and selection. After each amplification, the PCR products were phenol-chloroform extracted twice, ethanol precipitated, and resuspended in 20  $\mu$ l of TE buffer.

Typically, PCR amplifications were verified by agarose gel electrophoresis. In addition, a variety of controls were used to monitor the cyclic selection process. As one control, PCR "arms" (oligonucleotides of defined sequence that serve as primer hybridization sites) were placed on a nucleic acid that comprised a neomycin resistance-conferring gene. The resulting nucleic acid was mixed with the PCR-amplified cDNA and monitored at each selection by quantitative PCR. As another control, RNase P was followed in both the RNase P selected and the telomerase RNA component selected libraries.

- 49 -

Example 5RT-PCR protocol

The first strand cDNA was made in substantial accordance with the procedure described in Example 1.

- 5 Basically, RNA was purified from each telomerase fraction containing 0.1 to 1  $\mu$ g RNA; typical, about one-third to one-fifth of the RNA made from a 300  $\mu$ l fraction was used. The RNA was mixed with 40 to 80 ng random hexamer in 10  $\mu$ l, denatured for 10 min. at 95°C (using a thermal-cycling  
10 instrument), and chilled on ice. The denatured RNA and 6-mer were added to a reaction mixture containing 4  $\mu$ l of 5x 1st strand synthesis buffer supplied by the manufacturer of the reverse transcriptase (RTase, purchased from BRL), 2  $\mu$ l of 0.1 DTT, 1  $\mu$ l of 10 mM dNTP (each), 1  $\mu$ l of RNase  
15 inhibitor (Pharmacia), and water to a total volume of 9  $\mu$ l. The combined mixture was placed into a 42°C water bath. After 1-2 min. incubation, 1  $\mu$ l of Superscript™ II RTase (BRL) was added to the mixture. The incubation was continued for 60 min. at 42°C. The reaction was stopped by  
20 heating the tube for 10 min. at 95-98°C. The first strand cDNA was collected by brief centrifugation, aliquoted to new tubes, quickly frozen on dry ice, and stored at -80°C or used immediately.

Example 6

- 25 PCR amplification of cDNA with a specific primer set

For a 20  $\mu$ l PCR reaction with radioactively labeled nucleotides, 1  $\mu$ l of the cDNA prepared in accordance with the procedure of Example 5 was mixed with 20 pmol of primer 1, 20 pmol of primer 2, 2.5  $\mu$ l of 2.5 mM dNTP, 5  $\mu$ Ci of  
30 alpha -<sup>32</sup>p-dATP, 2 units of Taq polymerase (Boehringer-Mannheim), 0.2  $\mu$ g of T4 gene 32 protein (Boehringer-Mannheim), 2  $\mu$ l of 10x buffer (500 mM KCL, 100 mM Tris-HCl-pH8.3, and 20 mM MgCl<sub>2</sub>), and water to a total volume of 20

-50-

μl. One drop of mineral oil was then added to the tube.

The PCR amplification conditions for the telomerase RNA component clone were: 94°C for 45 sec., 60°C for 45 sec., 72°C for 1.5 min. The number of cycles differed depending on the type of purified materials used for RNA preparation but typically range from 18 to 25 cycles. As for all quantitative RT-PCR, several reactions with differing cycles were run for each sample to determine when the PCR amplification became saturated and non-linear.

For the RNase P used as a control, the PCR amplification conditions were: 94°C for 45 sec., 50°C for 45 sec., and 72°C for 1.5 min. Again, the number of cycles ranged from 15 to 22 cycles, depending on the nature of the samples. The sequences of the primers used for RNase P amplification are shown below:

P3: 5'-GGAAGGTCTGAGACTAG-3' (SEQ ID NO:16)

P4: 5'-ATCTCCTGCCCAGTCTG-3' (SEQ ID NO:17)

The PCR product obtained with these two primers is about 110 bp in size.

After PCR, the products (5 to 10 μl of the reaction mixture) were loaded onto a 6% native polyacrylamide gel and electrophoresed. After electrophoresis, the gel was dried and exposed to a PhosphorImager™ cassette or to autoradiographic film for analysis.

## Example 7

### Cloning the gene for the RNA component of human telomerase

The procedures used to clone the gene for the RNA component of human telomerase were carried out as generally described in Maniatis, et al., Laboratory Molecular Cloning Manual. A genomic DNA library of DNA from the human lung fibroblast cell line WI-38 inserted into phage lambda vector FIXII was purchased from Stratagene. The phage were plated at a concentration of about 25,000 plaques per plate

-51-

onto three sets of 15 (150 mm) plates. The plates were made with NZY agar and NZY top agarose; the cells used for the phage transformation were XL1BlueMRAP2 cells; and the transformants were grown overnight for about 16 hours at 37°C. The plates were then chilled at 4°C for about an hour, and then the plaques were "lifted" onto C/P nylon circles (filter paper from Bio Rad). This process was repeated to produce a duplicate set of lifted filters. The filters (in duplicate) were denatured, neutralized, equilibrated in 6x SSC buffer, exposed to UV irradiation to cross-link the nucleic acid to the filter, and then dried on blotter paper.

Prehybridization was conducted for one hour at 37°C in 50% formamide buffer. The filters were probed with an ~218 bp, radioactively-labeled, NotI fragment from clone pGRN7, which has been isolated by electroelution from a 5% polyacrylamide gel after separation by electrophoresis and then nick-translated with alpha-<sup>32</sup>P-dCTP using a nick-translation kit from Boehringer-Mannheim Biochemicals in accordance with the manufacturer's instructions. About 25 ng (~10 µCi label) of the probe were used per filter, and hybridization was conducted overnight at 37°C in 50% formamide hybridization buffer. After hybridization, the filters were washed at room temperature six times; the first three washes were with 6x SSC containing 0.1% SDS, and the last three washes were with 6x SSC alone. After an initial exposure of several duplicate filters in a PhosphorImager™ cassette to check hybridization efficiency and signal strength, the filters were washed at 65°C in 0.5x SSC. The filters were then placed under Kodak XAR5 film using two intensifier screens and then allowed to expose the film for about 100 hours at -70°C.

One strong signal emanated from the filter containing a phage, later designated 28-1, comprising the gene for the

-52-

RNA component of human telomerase. The plaque corresponding to the signal observed on the filter was used to make secondary plates, so that an isolated plaque (confirmed by probing with labeled pGRN7 nucleic acid) could be cultured for large-scale isolation of the phage DNA. Phage 28-1, available from the American Type Culture Collection under ATCC accession No. 75925, comprises an ~15 kb insert and comprises several restriction fragments that contain sequences that hybridize with RNA component sequences on pGRN7: a 4.2 kb *EcoRI* restriction enzyme fragment; a 4.5 kb *ClaI* restriction enzyme fragment, and a 2.5 kb *HindIII*-*SacI* restriction enzyme fragment. The latter fragment comprises the entire ~560 nucleotide sequence of the RNA component shown above and is believed to comprise the complete gene for the RNA component. The plasmid comprising the 2.5 kb *HindIII*-*SacI* restriction enzyme fragment in the pBluescript vector was designated plasmid pGRN33 and is available from the American Type Culture Collection under ATCC accession No. 75926. To the extent the human gene may comprise sequences other than those on the 2.5 kb fragment, those sequences can be isolated from phage 28-1 or from other phage clones identified by probing with the 2.5 kb fragment (or another probe of the invention).

The restriction enzyme fragments noted above were prepared in separate restriction enzyme digests; the products of the digests were separated by electrophoresis on a 0.7% agarose gel or, for the ~2.5 kb fragment only, a 3% polyacrylamide gel; and the desired bands were cut from the gel and prepared for subcloning either by using the GeneClean™ Kit II (from Bio101, Inc.) or by electroelution into Spectropor #2 dialysis tubing in 0.1x TBE at 100 V for two hours (for the ~2.5 kb fragment only).

These restriction enzyme fragments were subcloned into *E. coli* expression/mutagenesis plasmids derived from pUC-

based plasmids or from pBluescriptII plasmids that also comprise an SV40 origin of replication (but no SV40 promoter activity). The resulting plasmids can be used to prepare altered (mutated) RNA component nucleic acids for introduction into human or other eukaryotic cells for a variety of purposes, as described above in the Description of the Preferred Embodiments.

#### Example 8

##### Antisense plasmids for the RNA component of human telomerase

Antisense expression plasmids were prepared by PCR amplification of RNA component cDNA using the following primer sets: (1) NotB and G1, which produces an antisense nucleic acid that is smaller than the cDNA insert in the plasmid; and (2) NotB and R3C, which produces a full-length (relative to the insert in the plasmid) antisense nucleic acid. The nucleotide sequence of NotB is shown in Example 1, above: the nucleotide sequences of the G1 and R3 primers are shown below.

G1: 5'-GAGAAAACAGCGCGCGGGGAGCAAAAGCA-3' (SEQ ID NO:18)

R3C: 5'-GTTTGCTCTAGAATGAACGGTGGAAG-3' (SEQ ID NO:19)

After PCT amplification, the amplified fragments were cloned into an ~10 kb expression plasmid at a PmlI site: the plasmid comprises puromycin resistance-conferring, DHFR, and hygromycin B resistance-conferring genes as selectable markers, the SV40 origin of replication; the inducible human metallothionein gene promoter positioned for expression of the antisense strand of the gene for the RNA component of human telomerase (one could also use a stronger promoter to get higher expression levels), and the SV40 late poly A addition site.

The resulting plasmids (designated pGRN42 for the NotB/G1 product and pGRN45 for the NotB/R3C product) were transfected by the calcium phosphate procedure (see Maniatis, et al., supra) into the fibrosarcoma cell line

-54-

HT1080. HT1080 cells are normally immortal; expression of the antisense RNA for the RNA component of human telomerase should prevent the RNA component of human telomerase from association with the protein components, blocking the formation of active telomerase and rendering the cells mortal.

#### Example 9

##### Mouse Telomerase Activity Purification

Forty liters of mouse FM3A cells were grown in suspension in DMEM medium supplemented with 10% calf serum to a density of  $0.5 \times 10^5$  cells/ml. S-100 cytoplasmic extracts were prepared as described (Counter, et al. (1992) *EMBO J.* 11:1921-1929; Prowse, et al. (1993) *supra*) and glycerol and NaCl were added to a final concentration of 10% and 0.1 M, respectively. For purification of mouse telomerase activity, the S-100 extracts were passed through 30 ml of a DEAE-agarose column previously equilibrated in 1x hypo-buffer (Prowse, et al. (1993) *supra*) containing 0.1 M NaCl as well as several protease inhibitors. After collection, the flow through the column was washed with 3 volumes of hypo-buffer-0.1 M NaCl. Hypo-buffer containing increasing NaCl concentrations (0.2 M, 0.35 M, 0.5 M and 0.7 M) was used as eluant, and 100 ml fractions were collected at each salt concentration. Telomerase activity eluted at 0.35 M NaCl. This telomerase-containing fraction was then diluted with 1x hypo buffer to 0.1 M NaCl final concentration and loaded on a 10 ml of a spermine-agarose column previously equilibrated with 1x hypo-buffer-0.1 M NaCl. After collecting the flow through, the wash and elution steps were carried out as described previously (Prowse, et al. (1993) *supra*; the volume of each eluate was 20 ml and activity eluted between 0.35 M and 0.5 M NaCl. The lower salt fraction, containing most of the telomerase



-55-

activity was loaded onto an octyl-sepharose column equilibrated with 1x hypo-buffer-0.1 M NaCl. The column was washed as described previously and eluted with 1x hypo-buffer containing 1% triton X-100, fractions of 3 ml were collected, most of the telomerase activity was in fraction number 3.

Twenty  $\mu$ l of each fraction were used to assay telomerase activity as described (Prowse, et al. (1993) *supra*). RNA was prepared from all the column fractions by extracting 100  $\mu$ l of each fraction first with one volume of phenol and then with one volume of phenol/chloroform followed by ethanol precipitation (Sambrook, et al., (1989) *Molecular Cloning - a laboratory manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). RNA was run on a 6% acrylamide/urea gel at 20 W. RNA was electroblotted to a Hybond N+ membrane and hybridized with a 300 bp PCR fragment of mouse telomerase RNA (mTR) gene. Hybridization was done at 65°C in 1% BSA, 200 mM NaPO<sub>4</sub>, 15% formamide, 1 mM EDTA and 7% SDS. Filters were washed in 0.4x SSC, 0.1% SDS at 65°C.

#### Example 10

##### Mouse Genomic Library Screening

A genomic library from D3 embryonic stem cells cloned in  $\lambda$  EMBL3 was used for screening. Three to four genomes were plated for the primary screening using the strain LE392 (P2) as plating cells. A PCR product of 450 bp of the human telomerase RNA (hTR) gene was gel purified and radiolabeled by hexameter labeling (Sambrook, et al. (1989) *supra*) using high specific activity (3000 Ci/mmol) dNTPs. The sequences of the primers used to generate the probe were as follows:

u3b: 5'-GCCTGGAGGGGTGGTGGCCATTTTTTG-3' (SEQ ID NO:20)

ol3: 5'-GATCGGCGTTCCCCCACCAC-3' (SEQ ID NO:21).

-56-

The mouse library was probed with the human sequence at 55°C in a moderate stringency buffer (Sambrook, et al. (1989) *supra* containing 1% BSA, 500 mM NaPO<sub>4</sub>, 15% formamide, 1 mM EDTA and 7% SDS. The filters were washed at 55°C in 0.4x SSC and 0.1% SDS. Positive plaques were re-plated and probed again to further purify the positive lambda clones. After the isolation of single positive phage clones, 50 ml LE392(P2) culture was infected and DNA was prepared using the Qiagen Kit for lambda DNA purification. A restriction map with four different enzymes that do not cut lambda DNA sequences was done for each positive clone. Four different clones had the same pattern with each enzyme, moreover, the same size restriction fragment for each enzyme hybridized to the human probe in a Southern blot. A 5 Kb EcoRI genomic fragment containing the homology region of the human RNA was cloned into KS<sup>+</sup> Bluescript vector and a further restriction map was done. The restriction enzyme PstI cut within the homology region. Both PstI fragments were cloned and sequenced.

#### Example 11

##### RT-PCR Protocol

A 3 µg sample of total RNA from the FM3A cell line was mixed with 8 ng of random hexamers in a final volume of 10 µl, denatured at 95°C for 10 minutes and chilled on ice. The annealing mixture was added to the reverse transcription mixture under the same conditions as for primer extension. Reverse transcriptase was not added to a control tube. Incubation was for 60 minutes at 50°C. The reactions were stopped by heating the tubes at 95°C for 10 minutes. A 1 µl aliquot of each first strand cDNA was used for each PCR reaction. PCR reactions contained 1x PCR buffer provided with Taq polymerase, 5 mM dNTPs, 100 ng of

-57-

each primer, 0.1  $\mu$ g of T4 gene 32 protein and 2 units of Taq polymerase from Perkin-Elmer. The conditions of PCR amplification were: 94°C for 1 minute; 60°C for 45 seconds; and 72°C for 1.5 minutes. Typically, 35 to 40 cycles were carried out for a first amplification. For nested amplification, 1  $\mu$ l of the first PCR was used in a second PCR. For cloning, the PCR products were phenol extracted, precipitated and digested with restriction enzymes NotI and SalI, and cloned in KS+ Bluescript that was previously digested with NotI and SalI. Primers used were: First amplification:

mTR5b: 5'-CGTCGACTAGGGTCGAGGGCGGCTAGGCCT-3' (SEQ ID NO:22)  
mTR3: 5'-GGAGGCGGCCGCAGACGTTTGATTTTTTGAGGC-3' (SEQ ID NO:23)

Second amplification:

mTR5b: (see above)  
nest B: 5'-GGAGGCGGCCGCAGACGTTTGTTTTTTGAGGC-3' (SEQ ID NO:24).

### Example 12

#### 20 Mouse Inhibition/Elongation Experiments

Each oligonucleotide used in these experiments was gel purified on a 10% acrylamide-urea gel; the band corresponding to the unit length size was excised and eluted from the gel in water. After elution, oligonucleotides were further purified using a NAP-5 column (Pharmacia, Inc.). The concentration of each oligonucleotide was determined by measuring the O.D. at 260 nm. For both inhibition and priming experiments, the indicated amount of oligonucleotide was preincubated on ice for 30 min. with 20  $\mu$ l of a DEAE-agarose fraction containing telomerase activity, either pretreated or not with DNase-free RNase. After pre-incubation, 20  $\mu$ l of 2x telomerase reaction mix (100mM Tris-acetate, pH 8.5; 100 mM

-58-

potassium acetate, 4 mM dTTP, 4 mM dATP, 2 mM MgCl<sub>2</sub>, 2 mM spermidine, 2 mM EGTA, 10 mM 2-mercaptoethanol, 20  $\mu$ Ci of  $\alpha$ -<sup>32</sup>P dGTP (800 Ci/mmol, New England Nuclear)) was added and telomerase reactions were carried out as described.

- 5 For the inhibition studies, 1.0  $\mu$ g of telomeric oligonucleotide (T<sub>2</sub>AG<sub>3</sub>), was also added to the 2x reaction mix for the inhibition studies. All ddNTPs were used at a final concentration of 2 mM.

The sequence of the oligonucleotides used for  
10 inhibition and elongation experiments were as follows:

MI-2: ATGAAAATCAGGGTTAGG (SEQ ID NO:25)

MP-1: CCACAGCTAATGAAAATC (SEQ ID NO:26)

MP-4: CCACAGCTAATGAAAATCAGGGTTAGG (SEQ ID NO:27)

MI-3: TCACGTTCAAGGGTTAGG (SEQ ID NO:28)

- 15 MI-5: ATGAAAATCGCTA~~C~~CTAA (SEQ ID NO:29)

MP-3: CCCACAGCTAATGAAAAT (SEQ ID NO:30)

MP-4: CCCACAGCTAATGAAAA (SEQ ID NO:31).

### Example 13

#### Northern Blots of Cell Culture and Tissues

- 20 Total RNA from different mouse tissues was purchased from Clontech, and total RNA from pre-crisis and post-crisis *Mus spretus* fibroblasts was prepared from 90 mm tissue culture plates as described (Sambrook, et al., 1989). RNA concentration was determined measuring the  
25 absorbance at 260 nm in a spectrophotometer. Twenty  $\mu$ g of each RNA was run on a 6% acrylamide-7M urea gel and transferred to Hybond N+ membrane. Hybridization with the mouse telomerase RNA (mTR) probe was done in high stringency conditions as described in Sambrook, et al.  
30 (1989) *supra*.

Example 14Construction of a mouse knockout plasmid

Figure 6 shows the restriction map for approximately 15 kb surrounding the mouse telomerase RNA component gene in the mouse genome. For targeting a standard mouse knock out, vector pPNT was used (plasmid structure shown at bottom of the figure). To create the specific knockout plasmid, a 3.3 kb fragment of genomic DNA 5' region of the mouse gene was altered to add a *SacI* (*Sc*) site by site-directed mutagenesis. The 3.3 kb fragment was cloned into the *XbaI* site downstream from the neo gene in pPNT. In addition, a 4.0 kb genomic fragment from the 3' region flanking the mouse telomerase RNA gene was altered to add a *SacI* restriction site. This fragment was then cloned into the upstream *XhoI* site in the pPNT vector.

Example 15Identification and Isolation of RNA Component Nucleic Acids from Other Non-human Mammals

To illustrate how the reagents of the invention can be used to identify and isolate substantially homologous nucleic acids from other mammalian species, PCR primers complementary to human RNA component sequences were used to amplify homologous sequences in a PCR. An illustrative primer pair used to demonstrate this aspect of the invention is composed of primer +10, which has the sequence 5'-CACCGGGTTGCGGAGGGAGG-3' (SEQ ID NO:32), and primer R7 which has the sequence 5'-GGAGGGGCGAACGGGCCAGCA-3' (SEQ ID NO:33). Genomic DNA was prepared from chimpanzee, squirrel monkey, rhesus monkey, and baboon tissue and dissolved in TE buffer at a concentration of about 0.5 - 4 mg/ml.

For each tissue type, a PCR mixture was prepared, which mixture comprised: 1  $\mu$ L of genomic DNA, 48  $\mu$ L of Master Mix (Master Mix is composed of 1x TaqExtender™ buffer from Stratagene, 200  $\mu$ M of each dNTP, and 0.5  $\mu$ M of

-60-

each primer), and 0.5  $\mu$ L of a 1:1 mixture of Taq polymerase (5 units/ $\mu$ L, Boehringer-Mannheim):Tth polymerase (TaqExtender™ polymerase, from Stratagene). The reaction tubes were loaded onto a thermal cycler, which was

5 programmed to first heat the reaction mixture at 94°C for 5 minutes and then to perform 27 cycles of incubations at 94°C for 30 sec., 63°C for 10 sec., and 72°C for 45 sec. After the amplification reaction was complete, about 10 $\mu$ L of each reaction mixture were loaded onto a 2% agarose gel

10 for electrophoresis. After electrophoresis, staining of the gel, and UV irradiation, one could observe that each reaction mixture contained a band of the predicted (~200 bp) size. Nucleic acids from these bands can be cloned and sequenced and the remainder of the RNA component genes from

15 each of these mammalian species can be cloned as described above for the gene for the RNA component of human telomerase or mouse telomerase.

A similar procedure was used to clone and sequence the RNA components of rat, Chinese hamster and bovine

20 telomerase. PCR primers were designed to the conserved regions between the human and the mouse RNA components. In addition to mouse genomic sequence, a *Sall* restriction site was added onto the 5' primer and *NotI* restriction site added onto the 3' primer to allow efficient cloning. The

25 sequence of the primers are:

mTR 5': 5'-CGTCGACTAGCGCTGTTTTTCTCGCTGACT-3' (SEQ ID NO:34)  
Mtr 3': 5'-GGAGGCGGCCGCGAGGTGCACTTCCCACAGCTCAG (SEQ ID NO:35).

These primers were used to PCR a specific sequence of

30 the rat telomerase RNA component. Genomic DNA was isolated using standard procedures (Sambrook, et al., supra), and a region of the rat telomerase RNA gene was amplified with these two primers using procedures described in Sambrook, et al., supra. The PCR fragment was cloned and sequenced.

-61-

The sequence obtained between the PCR primers (269 nucleotides) showed a 74% homology to the mouse telomerase RNA gene. Since the sequence that was amplified between the primers was not used to select this clone, the 74%  
5 homology indicates that the correct gene had been cloned. To clone the full length of the gene, a genomic library was probed with the cloned rat fragment. Five positive clones were identified when five genome equivalents were screened. This suggests that the rat gene exists as a single copy in  
10 the rat genome, like the mouse and human genes in their genomes. The entire sequence of the rat gene is shown in Figure 7A-7B (SEQ ID NO:5).

Using the same primers described above, appropriate sized PCR fragments have been generated using genomic DNA  
15 from Cow, Mink, Chinese Hamster, African Green Monkey and the African horned frog *Xenopus*. Thus primers to conserved sequences in the human and mouse telomerase RNA genes can be generally useful in cloning telomerase RNA genes from many different mammalian species and even from other  
20 vertebrates. The entire sequences of Chinese hamster (SEQ ID NO:43) and cow (SEQ ID NO:44) have also been cloned using a procedure identical to the one used to clone the rat sequence (Figure 7A-7B).

#### Example 16

##### 25 Secondary structure of the RNA components

The cloned sequences for the human, mouse, rat, Chinese hamster and bovine telomerase RNA components have been used to determine a putative secondary structure folding of these RNA sequences (Figure 8A-8E). This  
30 secondary structure is important because it carries out the function of the RNA.

The foregoing examples describe various aspects of the invention and how certain nucleic acids of the invention

- 62 -

were made. The examples are not intended to provide an exhaustive description of the many different embodiments of the invention encompassed by the following claims.



-63-

Claims

We claim:

1. The RNA component of mouse telomerase in substantially pure form.
- 5 2. The RNA component of Claim 1 having a sequence identical to SEQ ID NO:4.
3. An oligonucleotide in substantially pure form comprising a sequence identical or exactly complementary to a contiguous sequence 10 to 500  
10 nucleotides in length of the RNA component of Claim 2.
4. The oligonucleotide of Claim 3 that is an oligodeoxyribonucleotide.
5. The oligonucleotide of Claim 3 that is an oligoribonucleotide.
- 15 6. The oligonucleotide of Claim 3 that, when bound to an RNA component of mouse telomerase, inhibits or blocks the activity of the telomerase.
7. A recombinant expression plasmid comprising the oligonucleotide of Claim 3 and further comprising a  
20 promoter positioned to drive transcription of an RNA complementary or identical in sequence to said oligonucleotide.
8. The recombinant expression plasmid of Claim 7, wherein said plasmid functions to produce the oligonucleotide  
25 in eukaryotic host cells.

-64-

9. The recombinant expression plasmid of Claim 7, wherein said plasmid functions to produce the oligonucleotide in prokaryotic host cells.
10. The recombinant expression plasmid of Claim 8, wherein  
5 said plasmid comprises a mouse gene for the RNA component of mouse telomerase.
11. The recombinant expression plasmid of Claim 10, wherein said gene comprises a nucleotide sequence according to SEQ ID NO:3.
- 10 12. A eukaryotic host cell transformed with a recombinant expression plasmid of Claim 7 that encodes an RNA molecule that associates with protein components of mouse telomerase to produce telomerase activity capable of adding sequences of repeating units of  
15 nucleotides to telomeres.
13. The host cell of Claim 11, wherein said repeating unit is 5'-TTAGGG-3'.
14. The host cell of Claim 11, wherein said repeating unit is not 5'-TTAGGG-3'.
- 20 15. The host cell of Claim 12, wherein said RNA molecule comprises SEQ ID NO:4.
16. The host cell of Claim 12, wherein said recombinant expression vector comprises a sequence of nucleotides defined by SEQ ID NO:3.
- 25 17. A coding region of an RNA component of a mammalian telomerase that comprises a sequence that is substantially homologous to a sequence in the RNA

-65-

component of Claim 2.

18. A method for producing a recombinant telomerase enzyme, said method comprising transforming a eukaryotic host cell that expresses protein components of telomerase with a recombinant expression vector that encodes an RNA component of Claim 17, and culturing said host cells transformed with said vector under conditions such that the protein components and RNA component are expressed and assemble to form an active telomerase molecule capable of adding sequences to telomeres of chromosomal DNA.
19. The RNA component of a mammalian telomerase in substantially pure form.
20. A DNA sequence encoding the RNA component of Claim 19.
21. A recombinant expression plasmid comprising the oligonucleotide of Claim 19 and further comprising a promoter positioned to drive transcription of an RNA complementary or identical in sequence to said oligonucleotide.
22. A recombinant expression plasmid comprising the oligonucleotide of Claim 20 and further comprising a promoter positioned to drive transcription of an RNA complementary or identical in sequence to said oligonucleotide.
23. The recombinant expression plasmid of Claim 21, wherein said plasmid functions to produce the oligonucleotide in a host cell.
24. The recombinant expression plasmid of Claim 22,

-66-

wherein said plasmid functions to produce the oligonucleotide in a host cell.

25. A eukaryotic host cell transformed with a recombinant expression plasmid of Claim 21 that encodes an RNA molecule that associates with protein components of a telomerase to produce telomerase activity capable of adding sequences of repeating units of nucleotides to telomeres.
26. A eukaryotic host cell transformed with a recombinant expression plasmid of Claim 22 that encodes an RNA molecule that associates with protein components of a telomerase to produce telomerase activity capable of adding sequences of repeating units of nucleotides to telomeres.
27. The RNA component of a non-human mammalian telomerase in substantially pure form.
28. A DNA sequence encoding the RNA component of Claim 27.
29. A recombinant expression plasmid comprising the oligonucleotide of Claim 27 and further comprising a promoter positioned to drive transcription of an RNA complementary or identical in sequence to said oligonucleotide.
30. A recombinant expression plasmid comprising the oligonucleotide of Claim 28 and further comprising a promoter positioned to drive transcription of an RNA complementary or identical in sequence to said oligonucleotide.
31. The recombinant expression plasmid of Claim 29,

-67-

wherein said plasmid functions to produce the oligonucleotide in a host cell.

32. The recombinant expression plasmid of Claim 30,  
wherein said plasmid functions to produce the  
oligonucleotide in a host cell.
33. A eukaryotic host cell transformed with a recombinant  
expression plasmid of Claim 29 that encodes an RNA  
molecule that associates with protein components of a  
telomerase to produce telomerase activity capable of  
adding sequences of repeating units of nucleotides to  
telomeres.
34. A eukaryotic host cell transformed with a recombinant  
expression plasmid of Claim 30 that encodes an RNA  
molecule that associates with protein components of a  
telomerase to produce telomerase activity capable of  
adding sequences of repeating units of nucleotides to  
telomeres.
35. An RNA component of rat telomerase in substantially  
pure form.
36. The RNA component of Claim 35 having a sequence  
encoded by SEQ ID NO:5.
37. DNA probes or primers comprising about 20 to 200 or  
more nucleotides encompassing conserved sequences  
between SEQ ID NO:1 and SEQ ID NO:3.
38. RNA probes or primers comprising about 20 to 200 or  
more ribonucleotides encoded by DNA encompassing  
conserved sequences between SEQ ID NO:1 and SEQ ID  
NO:3.

-68-

39. DNA sequences that hybridize under moderately stringent conditions to the conserved sequences of Claim 37.
40. A probe or primer comprising SEQ ID NO:34 OR SEQ ID  
5 NO:35.
41. An RNA sequence that hybridizes under moderately stringent conditions to the conserved sequences between SEQ ID NO:1 and SEQ ID NO:3.
42. A plasmid encoding a portion of the mouse genome  
10 wherein the telomerase RNA gene is replaced with a different DNA sequence.
43. A plasmid encoding a portion of the mouse genome normally encoding the telomerase RNA gene but wherein the bacterial neomycin gene replaces the telomerase  
15 RNA gene.
44. A mouse lacking telomerase.
45. The RNA component of Chinese hamster telomerase in substantially pure form.
46. The RNA component of Claim 45 having a sequence  
20 encoded by SEQ ID NO:43.
47. The RNA component of bovine telomerase in substantially pure form.
48. The RNA component of Claim 47 having a sequence encoded by SEQ ID NO:44.

-69-

49. DNA probes or primers comprising about 20 to 200 or more nucleotides encompassing conserved sequences between SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:43, and SEQ ID NO:44.
- 5 50. RNA probes or primers comprising about 20 to 200 or more ribonucleotides encoded by DNA encompassing conserved sequences between SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:43, and SEQ ID NO:44.
- 10 51. A DNA in substantially pure form that encompasses 5 or more of the conserved sequences between SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:43, and SEQ ID NO:44.
52. RNA encoded by or substantially homologous to the DNA of Claim 51.
- 15 53. A DNA sequence that hybridizes under moderately stringent conditions to the conserved sequences between SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:43, and SEQ ID NO:44.
- 20 54. An RNA sequence that hybridizes under moderately stringent conditions to the conserved sequences between SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:43, and SEQ ID NO:44.

1/14

GATCAGTTAGAAAGTTACTAGTCCACATATAAAGTGCCAAGTCTTGTACT 50  
CAAGATTATAAGCAATAGGAATTTAAAAAAGAAATTATGAAAAGTACTGACA 100  
AGATTTAGTGCCTACTTAGATATGAAGGGGAAAGAAGGGTTTGAGATAAT 150  
GTGGGATGCTAAGAGAATGGTGGTAGTGTTGACATATAACTCAAAGCATT 200  
TAGCATCTACTCTATGTAAGGTACTGTGCTAAGTGCAATAGTGCTAAAAA 250  
CAGGAGTCAGATTCTGTCCGTAAAAAACTTTACAACCTGGCAGATGCTAT 300  
GAAAGAAAAAGGGGATGGGAGAGAGAGAAGGAGGGAGAGAGATGGAGAGG 350  
GAGATATTTTACTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 400  
GGAGTTTATCTAACTGAATACGAGTAAACTTTTAAAGATCATCCTGTCAT 450  
TTATATGTAAACTGCACTATACTGGCCATTATAAAAAATTCGCGGCCCGGG 500  
TGCGGTGGCTCATACCTGTAATCCCAGCACTTTGGGAGGCCGAAGCGGGT 550  
GGATCACTTGAGCCCTGGCGTTCGAGACCAGCCTGGGCAACATGGTGAAA 600  
CCCCCGTCTCTACTAAAAACACAAAACTAGCTGGGCGTGGTGGCAGGCG 650  
CCTGTAATCCCAGCTACTCAGGAGGCTGAGACACGAGAATCGCTTGAACC 700  
CGGGAGCAGAGGTTGCAGTGAGCCGAGATCACGCCACTAGACTCCATCCA 750  
GCCTGGGCGAAAGAGCAAGACTCCGTCTCAAAAAAAAAAATCGTTACAAT 800  
TTATGGTGGATTACTCCCCTCTTTTACCTCATCAAGACACAGCACTACT 850  
TTAAAGCAAAGTCAATGATTGAAACGCCTTTCTTTCCTAATAAAAGGGAG 900  
ATTCAGTCCTTAAGATTAATAATGTAGTAGTTACACTTGATTAAAGCCAT 950  
CCTCTGCTCAAGGAGAGGCTGGAGAAGGCATTCTAAGGAGAAGGGGGCAG 1000  
GGTAGGAACCTCGGACGCATCCCACTGAGCCGAGACAAGATTCTGCTGTAG 1050  
TCAGTGCTGCCTGGGAATCTATTTTCAAAAGTTCTCCAAAAAATGTGAT 1100  
GATCAAACTAGGAATTAGTGTTCTGTGTCTTAGGCCCTAAAATCTTCCT 1150  
GTGAATTCCATTTTAAAGGTAGTCGAGGTGAACCGCGTCTGGTCTGCAGA 1200  
GGATAGAAAAAAGGCCCTCTGATACCTCAAGTTAGTTTCACCTTTAAAGA 1250

FIGURE 1A

SUBSTITUTE SHEET (RULE 26)



2/14

AGGTCGGAAGTAAAGACGCAAAGCCTTCCCGGACGTGCGGAAGGGCAAC 1300  
GTCCTTCCTCATGGCCGGAAATGGAACCTTAAATTTCCCGTTCCCCCAAC 1350  
CAGCCCGCCCGAGAGAGTGACTCTCACGAGAGCCGCGAGAGTCAGCTTGG 1400  
CCAATCCGTGCGGTGCGCGGCCGCTCCCTTTATAAGCCGACTCGCCCGGC 1450  
AGCGCACCGGGTTGCGGAGGGAGGGTGGGCCTGGGAGGGGTGGTGGCCAT 1500  
TTTTTGTCTAACCTAACTGAGAAGGGCGTAGGCGCCGTGCTTTTGCTCC 1550  
CCGCGCGCTGTTTTTCTCGCTGACTTTCAGCGGGCGGAAAAGCCTCGGCC 1600  
TGCCGCCTTCCACCGTTCATTCTAGAGCAAACAAAAATGTCAGCTGCTG 1650  
GCCCGTTTCGCCCCCTCCCGGGACCTGCGGCGGGTCGCTGCCAGCCCCCGA 1700  
ACCCCGCCTGGAGGCCGCGGTGCGCCGGGGCTTCTCCGGAGGCACCCACT 1750  
GCCACCGCGAAGAGTTGGGCTCTGTCAGCCGCGGGTCTCTCGGGGGCGAG 1800  
GGCGAGGTTACCGTTTCAGGCCGAGGAAGAGGAACGGAGCGAGTCCCG 1850  
CGCGCGGCGCGATTCCCTGAGCTATGGGACGTGCACCCAGGACTCGGCTC 1900  
ACACATGCAGTTCGCTTTCCTGTTGGTGGGGGAACGCCGATCGTGCGCA 1950  
TCCGTCACCCCTCGCCGGCAGTGGGGGCTTGTGAACCCCCAAACCTGACT 2000  
GACTGGGCCAGTGTGCTGCAAATTGGCAGGAGACGTGAAGGCACCTCCAA 2050  
AGTCGGCCAAAATGAATGGGCAGTGAGCCGGGGTTGCCTGGAGCCGTTCC 2100  
TGCGTGGGTTCTCCCGTCTTCCGCTTTTTGTTGCCTTTTATGGTTGTATT 2150  
ACAACTTAGTTCCTGCTCTGCAGATTTTGTTGAGGTTTTTGCTTCTCCCA 2200  
AGGTAGATCTCGACCAGTCCCTCAACGGGGTGTGGGGAGAACAGTCATTT 2250  
TTTTTTGAGAGATCATTTAACATTTAATGAATATTTAATTAGAAGATCTA 2300  
AATGAACATTGGAAATTGTGTTCCCTTAATGGTCATCGGTTTATGCCAGA 2350  
GGTTAGAAGTTTCTTTTTTGAAAAATTAGACCTTGGCGATGACCTTGAGC 2400  
AGTAGGATATAACCCCCACAAGCTT 2425

FIGURE 1B

SUBSTITUTE SHEET (RULE 26)

3/14

GGGUUGCGGAGGGAGGGUGGGCCUGGGAGGGGUGGUGGCCAUUUUUUGUC 50  
UAACCCUAACUGAGAAGGGCGUAGGCGCCGUGCUUUUGCUCUCCCGCGCGC 100  
UGUUUUUCUCGUGACUUUCAGCGGGCGGAAAAGCCUCGGCCUGCCGCCU 150  
UCCACCGUUCAUUCUAGAGCAAACAAAAAUGUCAGCUGCUGGCCCGUUC 200  
GCCCCUCCCGGGACCUGCGGCGGGUCGUGCCCAGCCCCCGAACCCCGCC 250  
UGGAGGCCGCGGUCGGCCGGGGCUUCUCCGGAGGCACCCACUGCCACCGC 300  
GAAGAGUUGGGCUCUGUCAGGCGCGGGUCUCUCGGGGGCGAGGGCGAGGU 350  
UCACCGUUUCAGGCCGCGAGGAAGAGGAACGGAGCGAGUCCCGCGCGCGGC 400  
GCGAUUCCCUGAGCUAUGGGACGUGCACCCAGGACUCGGCUCACACAUGC 450  
AGUUCGCUUUCUGUUGGUGGGGGGAACGCCGAUCGUGCGCAUCCGUCAC 500  
CCCUCGCCGGCAGUGGGGGGCUUGUGAACCCCCAAACCUGACUGACUGGGC 550  
559  
CAGUGUGCU

FIGURE 2

4/14

TTTTTTTTTTCCTCGTAATCTTTTTTTTTTGTTTTAAACACTGGAACCTGA  
TGTCTGGAGGACGGAGTCGGAGGATGTTTCGACCCTAATATCCGAGCCCAG  
TCGATGGGAACTTTAAGAAAAAGAAAGACCTTGAGTCATGGACCAACCGG  
TACGTGAGTGTTCTCTAGGCGGACGGAAGACAGTTTAAGACCTTAATTTC  
TAAACGCGGTGAAAAGGGGTGAAGGTGGGGGCCGACACCCTCACCTGACC  
CAACTTCCACCTTAAAAAAAAAAAAAAAAAATCACTTTTTTCCCCCCTA  
ACCTTTATAGGGGATGAAATATCCTACTTCAACTCTAGTATATTTTCA  
AACCAAGCCTCAGAGATGTGCGTGCCTGCGTGTGTGTGTGTGTATGTGTG  
TGTGTCTCACAGCAAGAAACAGATTTTATTATTTATTTTATTTATTTA  
TTTTTTGCAAGTGACTGGCTAGGAAGAGTGGGGAAGCGGGAGGACAAATG  
GGGAAGAGGGAGCATTTCGCAAGTGCTGGGCTCGACCAATCAGCGCGAG  
CCATGGGGTATTTAAGGTCGAGGGCGGCTAGGCCTCGGCACCTAACCTG  
ATTTTCATTAGCTGTGGGTCTGCTCTTTTGTCTCCGCCCCTGTTTTT  
CTCGCTGACTTCCAGCGGGCCAGGAAAGTCCAGACCTGCAGCGGGCCACC  
CGGCGTTCCCGAGCCTCAAAAACAAACGTGAGCGCAGGAGCTCCAGGTTT  
GCCGGGAGCTCCGCGCGCCGGGCCGCGCAGTCCCGTACCCGCTACAGGCC  
GCGGCGCTGGGGTCTTAGGACTCCGCTGCCGCGCGAAGAGCTGCGCTCT  
GTCAGCCGCGGGCGCGCGGGGCGTGGGGCAGGCGGGCGAGCGCGCGAGGA  
CAGGAATGGAACCTGGTCCGTGTTCCGTGTCTTACTGAGCTGTGGGAAGTG  
CACCGGACTCGGTTCTCACACCCCATTCCTGCTGGGGAAATGCCCGCTG  
CAGGGCGGGCCGCTAGAACCTGCGACTCTGGGGAAAGGGGCTTCGGTGTG  
AGACGGTAGCCAGCCAAAGGGTATATATCGCCCTCACGCCCGTCCCCCT  
CCACTTTTGTCTAATACTCCTGTTTCTGTTGTGTCAGATTTTGCAGGCGTT  
TCGCTGGCTCTGCCTGAACGAGCTATCAGCCATGTGGTCTTGGGGGTGG  
GGGTGGGGATGGGTTGTGTAGTGCTGGGAATGAACCTAGTTTCTAAGTTC  
TCTATCAAC

FIGURE 3

SUBSTITUTE SHEET (RULE 26)

5/14

CU CGACCAAUCAGCGCGAGCCAUGGGGUAUUUAAGGUCGAGGGCGGCUAG 50  
GCCUCGGCACCUAACCCUGAUUUUCAUUAGCUGUGGGUUCUGGUCUUUUG 100  
UUCUCCGCCCGCUGUUUUUCUCGCUGACUUCAGCGGGCCAGGAAAGUCC 150  
AGACCUGCAGCGGGCCACCCGGCGUCCCGAGCCUAAAAACAAACGUCA 200  
GCGCAGGAGCUCCAGGUUCGCCGGGAGCUCGCGCGCCGGGCCCGCCAGUC 250  
CCGUACCCGCCUACAGGCCGCGGCGCUGGGGUCUUAGGACUCCGCUGCCG 300  
CCGCGAAGAGCUGCGCUCUGUCAGCCGCGGGCGCGCGGGGCGUGGGGCAG 350  
GCGGGCGAGCGCGCGAGGACAGGAAUGGAACUGGUCCGUGUUCGGUGUCU 400  
UACUGAGCUGUGGGAAGUGCACCGGACUCGGUUCUCACACCCCAUUCCTG 450  
CUGGGGAAAUUGCCCCGUGCAGGGCGGGCCCGCUAGAACCUGCGACUCUGG 500  
GGAAAGGGGCUUCGGUGUGAGACGGUAGCCAGCC 534

FIGURE 4

SUBSTITUTE SHEET (RULE 26)

6/14

	<div> <div> <div>→ +1</div> <div>Mouse</div> </div> <div> <div>→ +1</div> <div>Human</div> </div> </div>	
Mouse	CUCGACCAAUCAGCGCGGCAUGGCGUAUUUAAGGUC--GAGGGCGG	46
Human	-----GGGUJUGCGGAGGAGGGUGGGCCUGGGAGGGGUG	34
	CUAGGC-CUGGGCAUUAAGCCUGAUUJUCAAUAGCUGUGGGJUCUGGUC	95
	GUJGGCAUUUUUGUUAAGCCUUAUGAGAGGGC-GUAGGCAGCGUGC	83
	JUUUGJUCJCCGC-CGCUGUUUUUCUCGCUGACUU-CAGCGGGCAGGAA	145
	JUUUGJUCJCCGC-CGCUGUUUUUCUCGCUGACUU-CAGCGGGC-GGAA	132
	AGJCCAGACCUGCGGCGGCCACCCGGCGUJCCCGAGCCUCAAPAAAGAA	195
	AGJCCAGACCUGCGGCGGCCACCCGGCGUJCCCGAGCC--AAAGAAAGAA	180
	CGUCAGC-GCAGGAGCUCCAGGUUCGCGGGGAGUCGCGGGCGCGGGCC	244
	UGUCAGCUGCUGGCGCGUUCGCGCGGCGGAGCCUGCGGGCGGGUUGCU	229
	GCCAG-UCCCGUACCCGCCUACAGGCCCGGGCGGGCCUGG-GJCUJA	291
	GCCAGCCCCGUAACCCGCCUGAGGCCCGGGCGGGCCUGGCUJCUCC	279
	GGA--C-UCCUGGCCCGCGGAAGAGJUCGCUUCUGUCAGCCGCGGG	337
	GGAGGCACCCACUGCCACCGCGAAGAGJUGGCUUCUGUCAGCCGCGGG	328
	CGCGGGGGGCGUGGGGCGAGG---CCGGGCGAGGCCGCGAGGAGGA	383
	CGCGGGGGGCGAGGGCGAGGJUCACCGJUUCAGGCCGCGAGGAGGA	377
	AUGGAACUGGUCGCGGJUCGGUGU-CUJACCUGAGCUGGGGAGUGUC	432
	AUGGAACUGGUCGCGGJUCGGUGU-CUJACCUGAGCUGGGGAGUGUC	426
	ACCCGGAACUCGGJUCACACA--A-CGCGAUUCCCGUGGGGAAAGUC	478
	ACCCGGAACUCGGJUCACACAUGCAGUUCGCUJUCUGUGGGUG-GGGG	475
	CGCGCUG-CAGGGCG-GGCCGUAAGAACCUGCGACJUGGGGAAAGGG	525
	AACGCUGAUCGUGCGCAUCCGJUCACCCUGCGGCGAGUGGGGECUUG	525
	--CUUC-GGUGUGA-GAC-GG-UAGCCAGCCAAAGGGUAUAUAUCGC	566
	AACCCCAACCGACUGACUGGGCGAGUGUCU-----	559
	CCUCACGCCCCGUC	580
	-----	559

FIGURE 5

SUBSTITUTE SHEET (RULE 26)




FIG. 6

8/14

+1  
→

```

hTR  GCTCCCTTTATAAGCCGACTCGCCCGGCAGCGCACCGGGTTGCGGAGGGA
bTR  CAGCCTTCAAAAATGAGGAGATCCGGGTGCGGAGGGTGGGCCCCGGGT
cTR  GCGAGAGCCGGCGCCGGCCAATCAGCGCGGCCACC-----CC
mTR  GCAAGTGCTGGGCTCGACCAATCAGCGCGGCCATGGGGTATTTAAGGTC
rTR  TGA CTATTAGGGCTCAGCCAATCAGCGCGAGCTGTCGGGTATTTAGGGAC

hTR  GGGTGGGCCTGGGAGGGGTGTGGC---CATTTTTTGTCTAACCCTAA-
bTR  GGGTGGGCCC--CGGGTTGG-TGGCAGCCATTTCTCATCTAACCCTAAT
cTR  GGGTACTTAAGGGCGACCTGGCGGGC-GGCT-GCCAGTCTAACCCTGAAT
mTR  GGGTATTTAAGGTCGA--GGGCGGCTAGGCCTCGGCACTAACCCTGATT
rTR  GGGTATTTAGGGACAA--GGGCGCGCGACTTCTGCGTCTAACCCTATT

hTR  -CTGAGAAGGGC-GTAGGCGCCGTGCTTTTGCTCCCGCGCGCTGTTTTT
bTR  T--GAGACAGGC-GTAGGCGCTGTGCTTTTGCTACCGCGCGCTGTTTTT
cTR  TCTGAG---AGCTGTGGGTACTGTGCTTTTCG-TCCTCCGCGCGCTGTTTTT
mTR  TTCATT---AGCTGTGGGTCTGTGCTTTTGCTTCCTCCGCGCGCTGTTTTT
rTR  GTTATA---GCTGTGGGTCTGTGCTTTTGCTTCCTCCGCGCGCTGTTTTT

hTR  CTCGCTGACTTTCAGCGGGC-GGAAAAGCCTCGGCCTGCGGCTTCCACC
bTR  CTCGCTGACTTTCAGCGGGC-GGAAAAGCCTCGGCCTACCGCATCCACC
cTR  CTCGCTGACTTTCAGCGGGC-GGAAAAGTCCAGACCTGCGGGGGCCATC
mTR  CTCGCTGACTTTCAGCGGGC-CAGGAAAGTCCAGACCTGCGGGGGCCACC
rTR  CTCGCTGACTTTCAGCGGGCCTGGAAAGTTCAGACCTGCGGGGGTCCACC

hTR  GTTCATTCTAGAGCAAAACAAAAA---TGTCAGGTGCTGGCCGTTCCGCC
bTR  ATCCAGTCTGCAACAAACAAAAA---TGTCAGCGCTGGCTCGCTCACC
cTR  GCGCGTTTTCCTCA-CCA-CAAAAAA---TGTCAGCGCTGGCGTATGTGCC
mTR  CGGCGTTCCCGAGCCT-CAAAAAACAAAGTCAAGCGCAAGGAGCTCCAGGT
rTR  GCGCATTTCTGGA-CCT-CAAAAAA---TGTCAGCGTAGGAAGCTC-TGGT

hTR  CCTCCC GGGA-CCTGCGGGGGGT--CGCTGCCAGCCCGGAACCCCGCC
bTR  TCTCCC GGGAACCTGCGGTGGT-CCGCGCGCCAGCCCGAGTGCCCGGCC
cTR  T-----GGAGCCT----TGCG-CCGCGCGCCAGCCCGCA--CCCGCC
mTR  TCGCCG-GGAGC-TCCGCGCGCGCGGGCCGCGCAGTCCCGTA--CCCGCC
rTR  GCC----AGAGC-TCCGCGCGCGCTGGGCGCGCCAGCCCGTA--CCCGCC

hTR  TGGAGGCCGCGGTTCGGCC-GGGCTTCTCCGGAGGCACCACTGCCACCG
bTR  TB-AGGCCGCGGTTCGGCC-GGGCTTCTCCGGAGGCACCACTGCCACCG
cTR  TB-AGGCCGCGGTTCGGC-TGGAG----TCTCGGGCTCC-GGTGCCGCGCG
mTR  TACAGGCCGCGGCTCGGCTTGGG----TCTTAGGACTCC-GGTGCCGCGCG
rTR  TGGAGGCCGCGGACGGCTTGGG----TCTTAGAACTCC-GGTGCCGCGCG

hTR  CGAAGAG-TTGGGCTCTGTACGCCGCGGGTCTCTCGGGGCGAGGGCGAG
bTR  TGAAGAG-TTGGGCTCTGTACGCCGCGGGTCTCTCGGTGGGCGAGGGCAT
cTR  CGAAGAGGT-AGACTCTGTACGCCGCGGG-CCGTGAGGGGTCTGGGGCGA-
mTR  CGAAGAGGTCCGCTCTGTACGCCGCGGG-CCGCGGGGGGTCTGGGGCGAG
rTR  TGAAGAGGT-AGTCTCTGTAGCTACGGG-GCACC GGCGCTGGGGTCTAG

```

FIGURE 7A  
SUBSTITUTE SHEET (RULE 26)

9/14

```

hTR  GTTCACCGTTTCAGGCAGC---AGGAAGAGGAACGGAGCGA-GTCCC-GCG
bTR  GGCTGTA-----ACCGC-AGGGAAAGGAACGGAGTGGGGTCCCCGCG
cTR  GCCGG--CAGC----GCCGCAAGCAGAGAAA-CGGAGCTG-GTCCC-GTG
mTR  GCCGGGCGAGC----GCCGCGAGGACAGGAAT-GGAAGTGGTCCCCGTG
rTR  GCCGGGAGAGC----GCCGCAAGGACAGTAAC-GGAAGTGGTCCCCGTGAG

hTR  CGCGGCGCGATTCCCTGAGCTATGGGACGTGCACCCAGGACTCGGCTCAC
bTR  CGCG-TGCG-TTCCCTGAGCTGTGGGACTTGCACCCGGGACTCGGCTCAG
cTR  AACGGTGAC-TTCCCTGAGTTGTGGGAATGCACCAGGAAGTGGTTCCC
mTR  TTCGGTGTC-TTACCTGAGCTGTGGGAAGTGCACCCGGAACTCGGTTCTC
rTR  TTCGGTGTC-TTTCCTGAGATGTGGGAAGTGCACCTGGAAGTCAAGTTCT

hTR  ACATGCAGTTCGCTTTCCTGTTGGTGGGGGAACCGGATCGTGCGCATC
bTR  ACATCTGAAAAAAAAAAAAA---TGAGGAGAT-CCTACCATATG-AAAC
cTR  ACAACCCCCAACCCCGC-----TGCGAATAAAGCTG-CTGCAAAGCGG
mTR  ACAACCCCCATTCCCGC-----TGCGAATAAGCCCGCTGCAGGGCGG
rTR  ACAACCCCCACTTCCCGC-----TGCGAAA-TGCTTGCTACCTGGCGG

hTR  CGTACCCCTCGCCGGCAGTGGGGGCTTGTGAACCCCAAACCTGACTGA
bTR  AATATGAAC-AAACCTTG-AGGTTGTGCTAAGTGAAG-TAAGTC-----
cTR  G-----CCCCTAGGACCTGGCAGCCCGAGGAATGGTG-CCAACGTGTGTGC
mTR  G-----CCGCTAGAACCTG-CGACTCTGGGGAAAGGGGCTTCGGTGTGAGA
rTR  GG-----CGCTAGAAC-TG-CAACCGGGAGGAACGGGGCCAAGGTGTGTGC

hTR  CTG-GGCCAGTGTGCTGC
bTR  ----AGCCATAGAAGGACAAATACTGTTACAATTC
cTR  ACATGCCAGAGTGGGCGATG
mTR  CGGTAGCCAGCCAAAGGGTATA
rTR  ACGAGGCCACGGTGCTC

```

FIGURE 7B






FIG. 8A




FIG. 8B




FIG. 8C





FIG. 8D



**THIS PAGE BLANK (USFPO)**

**PCT**WORLD INTELLECTUAL PROPE  
International Bi

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9601614A3

<b>(51) International Patent Classification <sup>6</sup> :</b> C12N 15/11, 15/54, 9/12, C12Q 1/68, C12N 5/10, A61K 31/70, C12N 15/00, A01K 67/027 // C12N 9/00, A61K 48/00		<b>A3</b>	<b>(11) International Publication Number:</b> WO 96/01614
			<b>(43) International Publication Date:</b> 25 January 1996 (25.01.96)
<b>(21) International Application Number:</b> PCT/US95/08620		<b>(74) Agents:</b> GRANAHAN, Patricia et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).	
<b>(22) International Filing Date:</b> 7 July 1995 (07.07.95)		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
<b>(30) Priority Data:</b> 08/272,102 7 July 1994 (07.07.94) US 08/330,123 27 October 1994 (27.10.94) US 08/387,524 13 February 1995 (13.02.95) US 08/485,778 7 June 1995 (07.06.95) US			
<b>(71) Applicants (for all designated States except US):</b> COLD SPRING HARBOR LABORATORY [US/US]; P.O. Box 100, Cold Spring Harbor, NY 11724 (US). GERON CORPORATION [US/US]; 200 Constitution Drive, Menlo Park, CA 94025 (US).		<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> ANDREWS, William, H. [US/US]; 6102 Park Avenue, Richmond, CA 94805 (US). AVILLON, Ariel, Athena [US/US]; 14 Fordham Road, Shoreham, NY 11786 (US). FENG, Junli [CN/US]; 1371 Greenbrier Road, San Carlos, CA 94070 (US). FUNK, Walter [CA/US]; 4858 Mendota Street, Union City, CA 94587 (US). GREIDER, Carol [US/US]; 87 Bay Drive East, Huntington, NY 11743 (US). MARHUENDA, Maria, Antonia, Blasco [ES/US]; 297 Mill Hill Road, Mill Neck,		<b>(88) Date of publication of the international search report:</b> 29 February 1996 (29.02.96)	
<b>(54) Title:</b> RNA COMPONENT OF TELOMERASE			
<b>(57) Abstract</b>  Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				



## INTERNATIONAL SEARCH REPORT

Inter. Application No.

PCT/US 95/08620

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/11 C12N15/54 C12N9/12 C12Q1/68 C12N5/10  
 A61K31/70 C12N15/00 A01K67/027 //C12N9/00,A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12Q A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 23572 (GERON CORP ;UNIV CALIFORNIA SAN FRANCISCO (US)) 25 November 1993 cited in the application	3-9
A	see page 17, line 24 - page 18, line 1 see page 22, line 13 - line 24 see page 25, line 3 - page 28, line 26 see page 31, line 15 - line 33 see page 48, line 9 - page 49, line 15 see examples 1,2,4,7,12,16 see claims	37-41
A	--- CURRENT OPINION IN GENETICS & DEVELOPMENT 4 (2). 203-211, April 1994 GREIDER, C. W. 'Mammalian telomere dynamics: Healing, fragmentation shortening and stabilization.' --- -/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

9 January 1996

Date of mailing of the international search report

26.01.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+ 31-70) 340-3016

Authorized officer

Andres, S

## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 95/08620

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GENES & DEVELOPMENT, vol. 8, no. 5, 1 March 1994 pages 563-575, AUTEXIER, C. & GREIDER, C. 'Functional reconstitution of wild-type and mutant Tetrahymena telomerase' cited in the application ----	
O,P, X	EIGHTY-SIXTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, TORONTO, ONTARIO, CANADA, MARCH 18-22, 1995. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 36 (0). 1995. 671-672, HARLEY, C. ET AL. 'Human telomerase inhibition and cancer.' see the whole document ----	19-26
P,X	WO,A,95 13382 (GERON CORP ;UNIV TEXAS (US); UNIV CALIFORNIA (US)) 18 May 1995 see page 23, line 7 - line 23 see page 49, line 30 - line 34 see page 54, line 10 - line 12 see page 57 - page 64 see page 76, line 7 - line 11 ----	3-9, 12-14,18
P,X	WO,A,95 13383 (GERON CORP ;UNIV TEXAS (US)) 18 May 1995 see the whole document ----	3-5
E	EP,A,0 666 313 (UNIV IOWA RES FOUND) 9 August 1995 see the whole document ----	19-26
T	SCIENCE (WASHINGTON D C) 269 (5228). 1267-1270, 1 September 1995 BLASCO, M. ET AL. 'Functional characterization and developmental regulation of mouse telomerase RNA.' see the whole document ----	1-34
T	SCIENCE (WASHINGTON D C) 269 (5228). 1236-1241, 1 September 1995 FENG, J. ET AL. 'The RNA component of human telomerase.' see the whole document -----	19-26

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/08620

**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 18 is directed (as far as in vivo methods are concerned) to a method of treatment of the (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of this compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Inv. onal Application No

PCT/US 95/08620

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9323572	25-11-93	AU-B- 4374093	13-12-93
		CA-A- 2135648	25-11-93
		EP-A- 0642591	15-03-95
-----			
WO-A-9513382	18-05-95	AU-B- 1178195	29-05-95
		AU-B- 1209095	29-05-95
		AU-B- 1330795	29-05-95
		WO-A- 9513381	18-05-95
		WO-A- 9513383	18-05-95
-----			
WO-A-9513383	18-05-95	AU-B- 1209095	29-05-95
		AU-B- 1330795	29-05-95
		WO-A- 9513381	18-05-95
		AU-B- 1178195	29-05-95
		WO-A- 9513382	18-05-95
-----			
EP-A-0666313	09-08-95	NONE	
-----			

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**